THE GUT-BRAIN NEXUS

THE LINK BETWEEN GUT MICROBIOTA AND NEURODEGENERATIVE DISEASES

Editors:
Ajay Kumar
Avinash Kumar

Bentham Books

The Gut-Brain Nexus: The Link Between Gut Microbiota and Neurodegenerative Diseases

Edited by

Ajay Kumar
Department of Pharmacology
Sardar Patel College of Pharmacy
Gorakhpur, UP-273013
India

&

Avinash Kumar
Department of Pharmaceutics
Sardar Patel College of Pharmacy
Gorakhpur, UP-273013
India

The Gut-Brain Nexus: The Link Between Gut Microbiota and Neurodegenerative Diseases

Editors: Ajay Kumar and Avinash Kumar

ISBN (Online): 979-8-89881-621-6

ISBN (Print): 979-8-89881-622-3

ISBN (Paperback): 979-8-89881-623-0

Published by Bentham Science Publishers Pte. Ltd. Singapore,

in collaboration with Eureka Conferences, USA.

First published in 2026.

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.
No. 9 Raffles Place
Office No. 26-01
Singapore 048619
Singapore
Email: subscriptions@benthamscience.net

CONTENTS

FOREWORD i

PREFACE ii

LIST OF CONTRIBUTORS iii

CHAPTER 1 GUT-BRAIN AXIS: EXPLORING THE COMPLICATED RELATIONSHIP BETWEEN THE GUT AND THE BRAIN 1

Astik Manju Ashesh, Pranay Wal, Dileep Kumar, Priyanka Tiwari, Avinash Kumar and Ajay Kumar

INTRODUCTION 2

ENTERIC NERVOUS SYSTEM 3

ROLE OF THE VAGUS NERVE 4

THE GUT-BRAIN COMMUNICATION 5

THE DIVERSITY AND COMPOSITION OF THE GUT MICROBIOTA 6

DETERMINANTS OF THE GUT MICROBIOTA 7

MECHANISMS OF GUT-BRAIN INTERACTION 9

Immune Pathway 10

Humoral/Metabolic Pathway 11

Endocrine Pathway 11

Neurological Pathway 12

INFLUENCE OF DIET AND LIFESTYLE 12

IMPACT OF GUT-BRAIN AXIS ON MENTAL HEALTH 15

CONCLUSION 16

LIST OF ABBREVIATIONS 17

REFERENCES 17

CHAPTER 2 UNRAVELLING THE ROLE OF MICROBIOTA IN BRAIN DISORDERS 27

Rati Kailash Prasad Tripathi

INTRODUCTION 28

COMPOSITION AND FUNCTIONS OF THE GUT MICROBIOME 30

Microbial Populations in the Human Gut 30

Metabolic and Immune Roles of the Gut Microbiota 31

MICROBIOTA DYSBIOSIS AND SYSTEMIC EFFECTS 32

Gut-related Disorders 32

Systemic Inflammation and Metabolic Disorders 33

Cardiovascular Disease 33

Autoimmune Diseases 33

Neuropsychiatric Disorders 33

THE GUT-BRAIN AXIS IN NEURODEGENERATIVE DISEASES 34

Pathways of Communication: Neural, Immune, and Endocrine 35

Neural Pathways 35

Immune Pathways 36

Endocrine Pathways 37

Influence of Microbial Metabolites on Brain Function 38

Short-Chain Fatty Acids (SCFAs) 38

Neuroactive Compounds 38

Toxins and Neurotoxic Metabolites 38

Role of the BBB in Microbiota-Mediated Effects 39

Microbial Influence on BBB Integrity 39

Microbial Impact on Neuroinflammation and BBB Disruption 39

MICROBIOME ALTERATIONS IN NEURODEGENERATIVE DISEASES 40
Alzheimer's Disease (AD) and Gut Dysbiosis 40
Parkinson's Disease (PD): A Microbiota Perspective 41
Amyotrophic Lateral Sclerosis (ALS) and the Gut Microbiome 41
Multiple Sclerosis (MS) and Microbial Changes 42
THE EARLY-LIFE MICROBIOME AND BRAIN DEVELOPMENT 43
Impact of Early-Life Microbial Exposures on Brain Health 43
Microbial Colonization at Birth 43
Gut Microbiome and Brain-Immune Interactions 44
Programming of Neurodevelopmental Trajectories 44
Prenatal and Postnatal Influences on Brain Function and Mental Health 44
Prenatal Influences on Brain Development 44
Impact of the Microbiome in Early Postnatal Life 44
Stress and the Microbiome in Early Life 45
The Microbiota in Developmental Neuropsychiatric Disorders 45
Autism Spectrum Disorder (ASD) 45
Attention Deficit Hyperactivity Disorder (ADHD) 45
Schizophrenia and the Microbiota 46
Neuroinflammation and Microbiota in Neuropsychiatric Disorders 46
THERAPEUTIC POTENTIAL OF TARGETING THE GUT MICROBIOME 46
Probiotics and Prebiotics in Neurodegenerative Diseases 46
Fecal Microbiota Transplantation 47
Dietary Interventions and Gut-Brain Health 48
Gut Microbiota Modulation through Pharmacological Agents 48
Microbiota-Targeted Drugs 49
Probiotic and Prebiotic-Based Pharmaceuticals 49
Personalized Medicine 49
CHALLENGES AND FUTURE DIRECTIONS 49
Limitations of Current Research in the Gut-Brain Axis 50
Complexity and Variability of the Microbiome 50
Lack of Standardization 50
Limited Long-Term Clinical Data 50
Ethical and Regulatory Concerns 50
Potential for Personalized Microbiome-Based Therapies 51
Microbiome Profiling 51
Customized Probiotics and Prebiotics 51
Challenges in Personalization 51
Integrative Approaches to Treat Neurodegenerative Diseases 52
Combination of Microbiome and Pharmacological Therapies 52
Dietary and Lifestyle Modifications 52
Holistic, Multi-Modal Treatments 52
Personalized, Integrative Care 52
CONCLUSION 53
REFERENCES 54

CHAPTER 3 THE GUT-BRAIN CONNECTION IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND ITS CONSEQUENCES 61
Sanjana Gupta, Mohamed Nihal P., Astik Manju Ashesh, Mohd Qasid Lari, Sandeep Kumar Singh and *Ajay Kumar*
INTRODUCTION 62
ALS: CLINICAL INSIGHTS 64

Diagnosis and Clinical Features of ALS 64
Biomarkers in ALS Diagnosis 66
RNA Binding Proteins (RBPs) 67
ALS-Related Genes 68
Non-Coding RNA 69
Others 70
PATHOPHYSIOLOGY 71
Role of Genetics in ALS Pathogenesis 71
BRAIN GUT DYSREGULATION 73
Historical Insights into ALS and Gut Involvement 73
Gut Microbiota Composition in ALS Patients 73
Gut-Brain Axis and ALS Pathogenesis 75
Gastrointestinal Dysfunction and its Clinical Implications in ALS 76
DISEASE PROGRESSION AND SYMPTOMATOLOGY 78
Pain and Sensory Symptoms in ALS 79
Gastrointestinal and Neurological Symptoms in ALS 79
Psychological and Cognitive Effects 80
CASE STUDIES AND CLINICAL TRIALS 80
Drugs used for ALS treatment 81
Riluzole (Rilutek®) 81
Other treatments 82
Gene Therapies 82
Immunotherapy 83
Stem Cell-Exosome Therapy (ASC-Exosome) 83
Potential and Ongoing Treatments 84
Discussion on Alternative Therapies (Probiotics, Prebiotics, Fecal Transplants) 84
FUTURE DIRECTIONS AND RESEARCH GAPS 86
CONCLUSION 86
REFERENCES 88

CHAPTER 4 THE LINK BETWEEN ALZHEIMER'S DISEASE AND GUT MICROBIOME: A GROWING RELATIONSHIP 99
Prajapati Manisha Anil, Sandesh Kumar Pattanaik and *Ashok Kumar Gupta*
INTRODUCTION 99
Alzheimer Diseases 99
Gut Microbiota 100
Gut-brain Axis 102
Evidence of Gut Microbiota Dysbiosis in Alzheimer's Disease 103
Impact on Neuroinflammation 103
Neurodegeneration 104
Neurotransmitter 106
Blood-Brain Barrier 106
The Beneficial Effect of Good Microbiota or Diet in AD 107
Modulation of Memory and Behaviour 107
Modulation of Neuroinflammation 108
Clearance of Amyloid Plaque 110
Reduction in Oxidative Stress 112
Alteration of Barrier Integrity 112
Improves Insulin Resistance 113
Clinical Studies 113
CONCLUSION 117

REFERENCES 118

CHAPTER 5 DECIPHERING THE CONNECTION BETWEEN GUT MICROBIOTA AND PARKINSON'S DISEASE 123
Anmol Kumar, Anjali Gond, Noopur Verma and *Ajay Kumar Gupta*
INTRODUCTION 124
Neurogastroenterology and its Relevance to PD 125
Types of Gut Microbiota and its Relation with Parkinson's Disease 127
LINK BETWEEN GUT FLORA AND PARKINSON'S DISEASE: UNDERLYING MECHANISM 129
α-Synuclein Misfolding and the Role of Gut Microbiota 130
Inflammation and Immune Responses 131
Role of Gastroparesis 131
Oxidative Stress and Mitochondrial Dysfunction 132
Inflammation 133
Mitochondrial Vulnerability 133
Weakened Antioxidant Defence 133
THERAPEUTIC INTERVENTION THROUGH GUT MICROBIOTA 134
Case Studies 136
CONCLUSION 136
REFERENCES 137

CHAPTER 6 THE GUT MICROBIOTA'S IMPACT ON THE EMERGENCE AND DEVELOPMENT OF NEURODEGENERATIVE DISEASES 141
Mohd Qasid Lari, Astik Manju Ashesh, Avinash Kumar, Dileep Kumar and Ajay Kumar
INTRODUCTION 142
GUT MICROBIOTA 143
MECHANISMS DRIVING THE IMPACT OF GUT MICROBIOTA ON NEURODEGENERATION 143
Modulation of the Immune System and Inflammation 144
Microbial Metabolites and Neurodegeneration 145
Gut-brain Axis and Neuromodulation 145
Blood Brain Barrier Dysfunction 146
GUT MICROBIOTA-LINKED NEURODEGENERATIVE DISORDERS 147
Alzheimer's Disease 148
Parkinson's Disease 150
Amyotrophic Lateral Sclerosis 152
CONCLUSION 154
LIST OF ABBREVIATIONS 154
REFERENCES 155

CHAPTER 7 THE GUT-BRAIN AXIS IN IRRITABLE BOWEL SYNDROME 162
Manisha Kawadkar, Deepika Devnani, Avinash Kumar, Dimak Chand Sahu and Arvind Kumar *Singh Chandel*
INTRODUCTION 162
The Gut-Brain Axis: Structure and Function 163
Central Nervous System (CNS) 163
Major Functions of CNS in the Gut-Brain Axis 163
ENTERIC NERVOUS SYSTEM (ENS) 164
Functions of ENS 164
Bidirectional Communication: CNS ↔ ENS 164

Role of Gut Hormones in Gut-Brain Signaling 165
Ghrelin and Gut-Brain Communication 165
Gut Hormones in Integrated Gut-Brain Functions 166
Clinical Presentation of IBS 166
Management 168
Importance of the Gut-Brain Axis in IBS Pathophysiology 168
Mechanisms of the Gut-Brain Axis in IBS 169
Neurotransmitters and the Enteric Nervous System (ENS) 169
Brain Processing of Gut Signals 169
Stress and Psychological Factors 169
Gut Microbiota and Immune System Interaction 169
Immune Activation and Inflammation 170
Impact of Gut-Brain Axis Dysfunction in IBS 170
Pharmacological Modulation of the Gut-Brain Axis in IBS 170
Targeting Visceral Hypersensitivity (Pain Modulation) 170
Antidepressants (SSRIs, SNRIs, Tricyclic Antidepressants) 170
Modulating Gut Motility 171
Modulating the Gut Microbiota (microbiome-gut-brain interaction) 171
Targeting the Stress Response (Psychological Modulation) 172
Altering the Gut Barrier Function (Leaky Gut Modulation) 172
NEUROTRANSMITTER-BASED DYSREGULATION IN IBS 172
Altered Serotonin Signaling in Irritable Bowel Syndrome (IBS) 172
Dysregulation of Dopamine and GABA in Visceral Sensitivity 173
ALTERED HPA AXIS ACTIVITY AND ELEVATED CORTISOL LEVELS IN RESPONSE TO STRESS 174
Pharmacological Agents Targeting the Gut-Brain Axis 175
GABA (Gamma-Aminobutyric Acid) Synthesis 175
Serotonin (5-HT) Synthesis 175
Novel and Emerging Pharmacological Approaches in IBS Treatment 178
Integrative Pharmacology: Combining Central and Peripheral Approaches in IBS Treatment 180
Combining Gut-Targeted and CNS-Active Drugs 180
Examples of Combining Gut-Targeted and CNS-Active Drugs 180
PERSONALIZED PHARMACOLOGICAL STRATEGIES BASED ON GUT-BRAIN INTERACTION PROFILES 181
Personalized Approaches Based on Gut-Brain Interaction Profiles 181
Pharmacological Landscape in modulating the Gut-Brain a\Axis Future Directions in Drug Development Targeting the Gut-Brain Axis for IBS 182
Future Directions in Drug Development Targeting the Gut-Brain Axis for IBS 183
CONCLUSION 184
CONSENT FOR PUBLICATION 184
REFERENCES 185

CHAPTER 8 THERAPEUTIC STRATEGIES FOR NEURODEGENERATIVE DISEASES *VIA* GUT MICROBIOTA MODIFICATION 190
Chitrali Talele, Chintan Aundhia, Dipali Talele, Manisha Lalan, A.K. Seth and *Mamta Kumari*
INTRODUCTION 191
IMPORTANCE OF GUT-BRAIN COMMUNICATION AND DYSBIOSIS 192
MODIFICATION OF THE GUT MICROBIOTA AND ITS APPLICATIONS IN NEURODEGENERATIVE DISEASES 195
Alzheimer's Disease 195

Parkinson's Disease 197
Amyotrophic Lateral Sclerosis 198
Multiple Sclerosis 198
CHALLENGES AND FUTURE RESEARCH DIRECTIONS 200
CONCLUSION 200
LIST OF ABBREVIATIONS 201
REFERENCES 201

CHAPTER 9 EXPLORING THE ROLE OF PROBIOTICS, PREBIOTICS, AND SYMBIOTICS IN THE MANAGEMENT OF NEURODEGENERATIVE DISEASES 209
Chintan Aundhia, Ghanshyam Parmar, Chitrali Talele, Piyush Kumar Sadhu and *A.K. Seth*
INTRODUCTION 209
Overview of Neurodegenerative Diseases 209
The Gut-Brain Axis 211
PROBIOTICS, PREBIOTICS, AND SYMBIOTICS: DEFINITIONS AND MECHANISMS 212
Definition and Characteristics 213
Probiotics 213
Prebiotics 214
Symbiotics 214
Mechanisms of Action 215
Modulation of Gut Microbiota 216
Interaction with the Gut-Brain Axis 217
SOURCES AND TYPES OF PROBIOTICS, PREBIOTICS, AND SYMBIOTICS 219
Natural and Synthetic Sources 219
Commonly Used Strains and Substances 220
Lactobacillus and Bifidobacterium (Probiotics) 220
Fructooligosaccharides and Inulin (Prebiotics) 221
Combination Products (Symbiotics) 222
IMPACT ON GUT MICROBIOTA AND METABOLITES 223
Alteration of Gut Microbial Composition 223
Production of Neuroactive Compounds 224
Influence on SCFAs 225
ROLE IN NEUROINFLAMMATION AND OXIDATIVE STRESS 226
Anti-Inflammatory Effects 226
Antioxidant Properties 227
Mechanisms of Neuroprotection 228
THERAPEUTIC POTENTIAL IN SPECIFIC NEURODEGENERATIVE DISEASES 229
Alzheimer’s Disease 229
Parkinson’s Disease 230
Huntington’s Disease 231
Amyotrophic Lateral Sclerosis (ALS) 232
FUTURE PROSPECTS AND CHALLENGES 234
CONCLUSION 234
LIST OF ABBREVIATIONS 235
REFERENCES 235

CHAPTER 10 DIET AND LIFESTYLE MANAGEMENT IN NURTURING THE GUT-BRAIN AXIS 245
Sandhya Vasanth, Sindhu Priya E. S., Mohammed Gulzar Ahmed, Sneh Priya and Alima Misiriya
INTRODUCTION 246

THE ROLE OF DIET IN THE GUT-BRAIN AXIS 248
Carbohydrates 248
Protein 248
Fats 248
Vitamins 248
Minerals 249
Prebiotics and Probiotics: Enhancing Gut Health 250
The Mediterranean Diet and Mental Health 250
Fermented Foods and Gut Microbiota 251
Fibre: Feeding the Gut Microbiome 252
LIFESTYLE FACTORS INFLUENCING THE GUT-BRAIN AXIS 252
Exercises 253
Nutraceuticals 255
Stress Management 256
Sleep and Circadian Rhythm 256
Physical Activity and Hydration 257
Pharmacological Therapies 257
Environment and Xenobiotics, like Food Additives and Alcohol 258
Personalised Genomics 259
CONCLUSION 261
REFERENCES 262

CHAPTER 11 GUT MICROBIOME MODULATION IN NEURODEGENERATIVE DISEASES: MARKETED PRODUCTS AND CHALLENGES 267
Surabhi Shakya, Anchal Srivastava, Alka Yadav, Anurag Verma and Amit Kumar Verma
INTRODUCTION 267
Association Between Gut Microbiota and Brain 268
Production of Microbial Metabolites 269
Dysbiosis Declines Neurotransmitter Production 270
Modulation of the Immune System 270
Activation of the Vagus Nerve 270
Impact of Synbiotics on the CNS 270
Marketed Products for Neuro-related Problems 271
VSL#3 272
SymproveTM 272
Sodium Oligomannate (GV-971) 273
Rifaximin 273
Challenges in the Treatment of Neurological Problems 273
Blood-Brain Barrier 274
Adverse Effect 274
Clinical Trials for Neurodegenerative Diseases 274
CONCLUSION 280
REFERENCES 281

SUBJECT INDEX 285

FOREWORD

In recent years, scientific exploration has unveiled a fascinating and intricate connection between two seemingly distant systems of the human body-the gut and the brain. What once appeared as isolated domains, operating independently, are now understood to be deeply intertwined through what we call the gut-brain axis. In this context, The Gut-Brain Nexus: The Link Between Gut Microbiota and Neurodegenerative Diseases offers a timely and groundbreaking examination of how our gut microbiota influences brain health and its critical role in neurodegenerative disorders.

This book delves into one of the most transformative areas of biomedical research today: the microbiome, the complex community of trillions of microorganisms residing in the gastrointestinal tract. Scientists have discovered that these microbes are far more than passive inhabitants; they actively interact with the brain through biochemical signaling, immune modulation, and metabolic pathways. Such findings have shattered long-held beliefs, revealing how gut health can influence mood, cognition, and even the progression of debilitating neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's.

In this book, the authors brilliantly synthesize cutting-edge research to illuminate the mechanisms by which gut dysbiosis-an imbalance in microbial composition-can exacerbate neuroinflammation, oxidative stress, and neuronal degeneration. They highlight the promise of gut-targeted interventions, such as probiotics, prebiotics, and dietary modifications, to slow disease progression and improve outcomes. By bridging the disciplines of neuroscience, microbiology, and clinical medicine, this book equips readers with a comprehensive understanding of the interplay between the gut and brain.

For clinicians, researchers, and curious readers alike, this work serves as a catalyst for rethinking traditional approaches to neurodegenerative diseases. It challenges us to consider how fostering gut health might hold the key to unlocking new therapies and preventive strategies for some of the most pressing neurological challenges of our time.

It is my hope that The Gut-Brain Nexus will inspire continued inquiry and innovation, igniting collaboration across fields to ultimately improve the lives of millions. Prepare to embark on an enlightening journey that redefines the way we view the brain, the gut, and their profound interdependence.

Rikeshwer Prasad Dewangan
Medicinal Chemistry & Peptide Research Laboratory
Department of Pharmaceutical Chemistry
School of Pharmaceutical Education and Research
Jamia Hamdard, New Delhi-220062
India

PREFACE

In recent years, the intricate relationship between the gut and brain has emerged as a pivotal focus of scientific research, reshaping our understanding of human health and disease. The Gut-Brain Nexus: The Link Between Gut Microbiota and Neurodegenerative Diseases delves into this burgeoning field, illuminating how the dynamic interplay between the gut microbiota and the central nervous system influences the onset, progression, and potential treatment of neurodegenerative diseases.

This book serves as a bridge between the expanding body of microbiome research and the urgent need for novel therapeutic strategies for disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. It explores the bidirectional communication between the gut and the brain, mediated by an intricate network of neural, hormonal, and immune pathways, collectively referred to as the gut-brain axis.

Each chapter is carefully curated to provide a comprehensive analysis of the latest scientific findings, highlighting the roles of microbial diversity, dysbiosis, and microbial metabolites in neurodegenerative disease pathogenesis. Through the lens of multidisciplinary research, this book brings together perspectives from microbiology, neurology, immunology, and systems biology to present a holistic view of the gut-brain interface.

While the primary audience includes researchers, clinicians, and students in the fields of neuroscience, gastroenterology, and microbiology, this book also aims to engage readers outside of these disciplines by emphasizing the broader implications of gut-brain interactions for overall health and well-being. By fostering a deeper understanding of the gut-brain nexus, we hope to inspire innovative approaches to prevent, manage, and potentially reverse neurodegenerative diseases.

As you journey through the chapters of this book, we invite you to explore the profound and often surprising connections between two seemingly distant systems of the body. In doing so, we hope to ignite further inquiry and collaboration in this exciting frontier of science, with the goal of transforming human health.

Ajay Kumar
Department of Pharmacology
Sardar Patel College of Pharmacy
Gorakhpur, UP-273013
India

&

Avinash Kumar
Department of Pharmaceutics
Sardar Patel College of Pharmacy
Gorakhpur, UP-273013
India

List of Contributors

Ajay Kumar	Department of Pharmacology, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India
Ajay Kumar Gupta	School of Pharmaceutical Science (formerly University Institute of Pharmacy), Chhatrapati Shahu Ji Maharaj University (formerly Kanpur University) campus, Kanpur 208024, India
Amit Kumar Verma	Department of Pharmacy, MJP Rohilkhand University, Bareilly, India
Alima Misiriya	Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to Be University), Mangalore, 575018, Karnataka, India
Alka Yadav	Rohilkhand College of Pharmacy, BIU, Bareilly, India
Anchal Srivastava	School of Pharmaceutical Sciences, Maharishi University of Information Technology, Lucknow, India
Anmol Kumar	School of Pharmaceutical Science (formerly University Institute of Pharmacy), Chhatrapati Shahu Ji Maharaj University (formerly Kanpur University) campus, Kanpur 208024, India
Anjali Gond	Department of Biotechnology, Institute of Applied Science and Humanities, GLA University, Mathura, 281406, Uttar Pradesh, India
Anurag Verma	College of Pharmacy, Teerthankar Mahaveer University, Moradabad, India
Arvind Kumar Singh Chandel	School of Engineering, University of Limerick, Limerick, V94 T9PX, Ireland
Astik Manju Ashesh	Department of Pharmacology, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India
Ashok Kumar Gupta	School of Pharmacy, Sharda University, Knowledge Park-3, Greater Noida, U.P-201306, India
Avinash Kumar	Department of Pharmaceutics, Sardar Patel College of Pharmacy, Gorakhpur, India-273013, India
A.K. Seth	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, 391760, India
Chintan Aundhia	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, 391760, India
Chitrali Talele	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, 391760, India
Deepika Devnani	School of Pharmacy, GH Raisoni University, Saikheda, Pandhurna (M.P), India
Dileep Kumar	Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India- 576104, India
Dimak Chand Sahu	School of Pharmacy, GH Raisoni University, Saikheda, Pandhurna (M.P), India
Dipali Talele	School of Pharmacy, Vishwakarma University, Survey No 2,3,4 Laxmi Nagar, Kondhwa, Budruk, Pune 411048, India
Ghanshyam Parmar	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, 391760, India

Mamta Kumari	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, 391760, India
Manisha Kawadkar	School of Pharmacy, GH Raisoni University, Saikheda, Pandhurna (M.P), India
Manisha Lalan	Department of Pharmaceutics, Parul University of Pharmacy & Research, Faculty of Pharmacy, Parul University, Limda, Waghodia-391760, Vadodara, Gujarat, India
Mohamed Nihal P.	Department of Pharmaceutical Chemistry, P.A. College of Pharmacy, Mangalore, Karnataka, 574153, India
Mohammed Gulzar Ahmed	Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to Be University), Mangalore, 575018, Karnataka, India
Mohd Qasid Lari	Department of Pharmacology, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India
Noopur Verma	School of Pharmaceutical Science (formerly University Institute of Pharmacy), Chhatrapati Shahu Ji Maharaj University (formerly Kanpur University) campus, Kanpur 208024, India
Piyush Kumar Sadhu	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, 391760, India
Prajapati Manisha Anil	School of Pharmacy, Sharda University, Knowledge Park-3, Greater Noida, U.P-201306, India
Pranay Wal	Pranveer Singh Institute of Technology, Kanpur, U.P., 209305, India
Priyanka Tiwari	Department of Pharmaceutical Chemistry, KLE College of Pharmacy, Bengaluru, KLE Academy of Higher Education & Research, Karnataka, 560010, India
Rati Kailash Prasad Tripathi	Department of Pharmaceutical Sciences, Sushruta School of Medical and Paramedical Sciences, Assam University (A Central University), Silchar, Assam, India
Sanjana Gupta	Department of Pharmaceutics, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India
Sandeep Kumar Singh	Department of Pharmaceutical Science and Technology, Madan Mohan Malaviya University of Technology, Gorakhpur, Uttar Pradesh, India
Sandhya Vasanth	Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to Be University), Mangalore, 575018, Karnataka, India
Sandesh Kumar Pattanaik	School of Pharmaceutical Sciences, Siksha 'O' Anusandhan Deemed to be University, Bhubaneswar, Odisha-751003, India
Sindhu Priya E. S.	Department of Pharmacology, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to Be University), Mangalore, 575018, Karnataka, India
Sneh Priya	Department of Pharmaceutics, N.G.S.M Institute of Pharmaceutical Science, Nitte (Deemed to Be University), Mangalore, 575018, Karnataka, India
Surabhi Shakya	Department of Pharmacy, MJP Rohilkhand University, Bareilly, India

CHAPTER 1

Gut-Brain Axis: Exploring the Complicated Relationship Between the Gut and the Brain

Astik Manju Ashesh[1], Pranay Wal[2], Dileep Kumar[3], Priyanka Tiwari[4], Avinash Kumar[5] and **Ajay Kumar[1,*]**

[1] *Department of Pharmacology, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India*

[2] *Pranveer Singh Institute of Technology, Kanpur, UP-209305, India*

[3] *Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka-576104, India*

[4] *Department of Pharmaceutical Chemistry, KLE College of Pharmacy, Bengaluru, KLE Academy of Higher Education & Research, Karnataka-560010, India*

[5] *Department of Pharmaceutics, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India*

Abstract: The gastrointestinal system and the brain are connected by a vast communication network known as the gut-brain axis. This bidirectional relationship includes a number of channels, such as immunological, hormonal, and neurological mechanisms. Recent studies have revealed the tremendous effects of gut bacteria on behavior and brain function, indicating that the gut may have an impact on neurological illnesses, mental health, and cognitive performance. For example, diseases including autism spectrum disorders, anxiety, and depression have been connected to changes in the composition of the gut microbiota. Conversely, brain activity can influence gut physiology, demonstrating the reciprocal nature of this relationship. The body's reaction to stress is also greatly influenced by the gut-brain axis, and alterations in the gut microbiota brought on by stress may exacerbate gastrointestinal disorders. Understanding this complex relationship offers potential therapeutic avenues for treating both gastrointestinal and neurological conditions. This chapter elucidates the intricacies of this crucial relationship and emphasizes the importance of the gut-brain axis, focusing on an extensive knowledge of the way our gut and brain relate to promote general well-being. The continuing research on the gut-brain axis has the potential to completely transform our approach to health.

Keywords: Gut-brain axis, Gut microbiota, Enteric nervous system, Neurodegenerative disorders, Mood disorders.

[*] **Corresponding author Ajay Kumar:** Department of Pharmacology, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India; E-mail: ajaykumarbp@gmail.com

INTRODUCTION

The gut-brain axis is a network of two-way communication involving the brain and the gastrointestinal system. In addition to being anatomical, this network also includes humoral, immunological, metabolic, and endocrine pathways of communication. The gut and the brain are connected by the Autonomic Nervous System (ANS), the HPA axis, along with nerves in the Gastrointestinal (GI) tract. This enables the gut to influence mental health, mood, and cognition, whereas the brain can influence intestinal processes, such as the activity of functional immune effector cells.

The gut microbiota interacts through the host's metabolism, controls a number of its metabolic processes, and establishes a functionally linked gut-organ axis [1 - 3]. The Central Nervous System (CNS) is significantly impacted by the gut bacteria. Several preclinical studies have shown that the gut microbiota and the brain are connected by bidirectional signal transduction, involving pathways such as gut-brain communication, immunologic barrier, and neuroendocrine signal transduction [4]. The gut microbiota, an extensive microbial ecosystem found in an organism's digestive system, is colonized at birth by maternal genes and evolves as a result of dietary practices and environmental cues [5].

Disorders in the functional gastrointestinal tract have been connected to a variety of mood disorders, such as autism spectrum disorders, anxiety, and depression. However, psychiatric comorbidities in GI disorders, like IBS and IBD, are often associated with alterations in the gut flora [6]. Furthermore, studies have shown that fetal and neonatal brain development may be influenced by the makeup of gut bacteria [7]. There is also evidence that the gut microbiota's impact on cognitive function is influenced by nutrition [8].

In order to maintain internal homeostasis and support its existence, the gut microbiota produces a variety of tiny molecules and metabolites, helping to regulate the host's physiological processes [9]. A shift in the microbiota of the gut, such as a rise in pathological microbes and a fall in symbiotic bacteria, may result in dysbiosis. This may lead to the production of metabolites, as well as the disruption of normal physiological and biochemical processes, causing pathological alterations in the host [10, 11]. (Fig. **1**)



Fig. (1). A possible link between gut and brain health is depicted in the diagram. A healthy brain is linked to a normal gut microbiome, whereas dysbiosis may raise the possibility of neurodegenerative illnesses, including Parkinson's and Alzheimer's.

ENTERIC NERVOUS SYSTEM

The Enteric Nervous System (ENS), often referred to as the “brain within the gut” or “second brain,” is made up of an inner submucosal plexus and an outer myenteric plexus and shares anatomical similarities with the brain [12, 13]. The formation, maintenance, and regulation of ENS neurons are regulated by gut bacteria, especially those producing and metabolizing hormones. The majority of enteric neurons are developed during embryogenesis and the early postnatal period, according to research involving germ-free mice [14, 15]. A number of neural crest cells expressing the transcriptional activator protein Sox10 colonize the foregut, multiply, and eventually spread throughout the whole bowel to produce neurons and glial cells [16]. The growth of enteric neurons requires the presence of microbial cells, according to a study conducted on mice. The scientists claim that when the microbiota has recolonized the gut of germ-free mice for three to fifteen days, neuroepithelial stem cells produce the protein Nestin and display the nuclear protein Ki67. Nestin keeps neuronal death and neurogenesis in balance, and the protein Ki67 is linked to rRNA transcription [17 - 19]. Therefore, a lack of any one of these proteins indicates a deterioration in Neural Stem Cells' (NSCs') capacity to regenerate injured cells [20].

CHAPTER 2

Unravelling the Role of Microbiota in Brain Disorders

Rati Kailash Prasad Tripathi[1,*]

[1] *Department of Pharmaceutical Sciences, Sushruta School of Medical and Paramedical Sciences, Assam University (A Central University), Silchar, Assam, India*

Abstract: The gut microbiota, a diverse and dynamic community of microorganisms residing in the gastrointestinal tract, has emerged as a critical player in maintaining brain health and contributing to the pathogenesis of neurological disorders. This chapter explores the intricate connections between the gut and brain, collectively referred to as the gut-brain axis, and explores its implications in various brain disorders, including neurodegenerative diseases, developmental disorders, and mental health conditions. Key topics include the composition and functions of the gut microbiome, pathways of communication *via* neural, immune, and endocrine mechanisms, and the influence of microbial metabolites on brain function. Particular attention is given to the role of gut dysbiosis in exacerbating neuroinflammation, amyloidogenesis, oxidative stress, and immune dysregulation, which are critical contributors to neurodegeneration. Emerging evidence on microbiome alterations in Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other disorders is reviewed, highlighting the potential of microbiome-targeted interventions. Therapeutic strategies such as probiotics, prebiotics, fecal microbiota transplantation, and dietary modulation are discussed alongside the challenges of translating microbiome research into clinical applications. The chapter concludes with an emphasis on interdisciplinary research and the potential for personalized microbiome-based therapies, underscoring the gut microbiome's transformative role in understanding, preventing, and managing brain disorders. This evolving field offers a promising avenue for advancing neurotherapeutics and improving patient outcomes.

Keywords: Gut microbiota, Gut-brain axis, Neurodegenerative diseases, Neuroinflammation, Microbiome dysbiosis, Amyloidogenesis, Oxidative stress, Blood-brain barrier, Immune dysregulation, Short-chain fatty acids (SCFAs).

[*] **Corresponding author Rati Kailash Prasad Tripathi:** Department of Pharmaceutical Sciences, Sushruta School of Medical and Paramedical Sciences, Assam University (A Central University), Silchar, Assam, India;
E-mail: rati.tripathi.phe09@iitbhu.ac.in

Ajay Kumar & Avinash Kumar (Eds.)

INTRODUCTION

The intricate relationship between the gut and the brain has emerged as one of the most fascinating areas of biomedical research in recent decades, reshaping our understanding of human physiology and health [1]. Central to this interaction is the gut microbiota, a complex and dynamic community of microorganisms that inhabit the human gastrointestinal tract. These microbial populations are far from passive; they play vital roles in maintaining homeostasis and influencing a range of physiological functions, including immune regulation, metabolic activity, and neurological health. While the gut microbiota has traditionally been studied in the context of digestive health, its profound impact on brain function and its potential role in neurological disorders have become increasingly evident [2, 3]. The Gut-Brain Axis (GBA), a bidirectional communication system between the gut and the brain, has become a focal point in neuroscience, offering intriguing insights into how microorganisms residing in the gastrointestinal tract influence brain health and behavior [4].

The concept of the GBA is rooted in an intricate network of signalling pathways, including the immune system, hormonal pathways, and the autonomic nervous system. These systems work together to relay messages between the gut and the brain, with the microbiota acting as a key mediator in this communication [5]. The influence of the microbiota on brain function is not merely speculative; studies have demonstrated that alterations in gut microbiota composition, also known as dysbiosis, can lead to significant changes in brain function and behavior. For instance, shifts in microbiota diversity have been associated with mental health conditions such as depression and anxiety, and evidence suggests that microbial imbalances may even play a role in the onset of neurodegenerative diseases [6]. Understanding the mechanisms through which the microbiota influences brain function requires an interdisciplinary approach, integrating microbiology, neuroscience, immunology, and psychiatry. Research has shown that microbial metabolites, such as short-chain fatty acids, neurotransmitters, and immune-modulating molecules, can directly impact the brain by influencing the blood-brain barrier, modulating neuroinflammation, and even affecting neuroplasticity [7, 8]. Additionally, gut-derived metabolites can interact with the central nervous system by stimulating vagal afferent fibers, which transmit signals from the gut to the brain. These interactions are thought to impact the development and progression of brain disorders, providing novel therapeutic avenues for intervention [9].

One of the most significant developments in recent years is the growing body of evidence suggesting that gut microbiota manipulation could potentially serve as a treatment for various brain disorders [10, 11]. Strategies such as probiotics,

prebiotics, fecal microbiota transplantation, and dietary modifications are being explored to restore balance to the gut microbiome, with the aim of alleviating symptoms of neurological and psychiatric conditions [12 - 14]. However, while the therapeutic potential is immense, the complexity of the microbiota and its interactions with the brain presents significant challenges. The diverse composition of the microbiota varies greatly among individuals, and the factors that influence its composition, such as diet, genetics, environment, and lifestyle, further complicate the task of understanding and manipulating this ecosystem for therapeutic purposes. In addition to the direct effects of microbiota on the brain, there is growing evidence suggesting that early life microbial exposures can shape brain development and influence the long-term risk of developing psychiatric and neurological disorders [15, 16]. The prenatal and postnatal microbiota, influenced by factors such as birth mode, breastfeeding, and early diet, may play a pivotal role in shaping the brain's immune system, neurotransmitter systems, and overall cognitive function. The microbiota's role in early brain development may have lasting implications for mental health, with dysbiosis during critical periods of development linked to an increased risk of conditions such as autism, Attention-Deficit/Hyperactivity Disorder (ADHD), and schizophrenia [17, 18]. Furthermore, research into the role of the microbiota in neurodegenerative diseases is gaining momentum, with studies suggesting that gut dysbiosis may contribute to the onset and progression of conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis [19, 20]. The microbiota's ability to modulate inflammation, influence the blood-brain barrier, and produce neuroactive compounds provides a potential mechanistic link to neurodegeneration [21 - 24]. In Alzheimer's disease, for example, changes in the gut microbiota have been observed alongside the accumulation of amyloid plaques and tau tangles, hallmark features of the disease. These findings suggest that the microbiota may play a role in the pathogenesis of Alzheimer's, raising the possibility of microbiota-based interventions as a means of slowing disease progression or alleviating symptoms [25].

As we unravel the complex interactions between the microbiota and the brain, it is clear that the microbiome represents a vast, untapped frontier in the study of brain disorders. The therapeutic potential of microbiota-based treatments is enormous, offering the possibility of new, non-invasive approaches to managing and even preventing neurological and psychiatric conditions [26]. However, much remains to be understood about the precise mechanisms involved, and further research is needed to translate these discoveries into effective clinical interventions. Understanding the role of early-life microbiome in brain development can open up new avenues for preventive interventions aimed at mitigating the risk of developing these disorders.

CHAPTER 3

The Gut-Brain Connection in Amyotrophic Lateral Sclerosis (ALS) and Its Consequences

Sanjana Gupta[1], Mohamed Nihal P.[2], Astik Manju Ashesh[3], Mohd Qasid Lari[3], Sandeep Kumar Singh[4] and **Ajay Kumar[3,*]**

[1] Department of Pharmaceutics, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India

[2] Department of Pharmaceutical Chemistry, P.A. College of Pharmacy, Mangalore, Karnataka-574153, India

[3] Department of Pharmacology, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India

[4] Department of Pharmaceutical Science and Technology, Madan Mohan Malaviya University of Technology, Gorakhpur, Uttar Pradesh, India

Abstract: Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disorder characterized by the progressive degeneration of motor neurons, leading to severe muscle weakness, respiratory failure, and eventual mortality. Despite significant advances in understanding its pathology, ALS remains a complex condition with a multifactorial etiology, including genetic predispositions, oxidative stress, and environmental influences. The gut-brain axis has emerged as a pivotal focus in ALS research, revealing bidirectional interactions mediated by neural and immune pathways. Dysbiosis in gut microbiota is implicated in exacerbating neuroinflammation and accelerating disease progression, while therapeutic strategies targeting the gut microbiome, including probiotics, prebiotics, and fecal microbiota transplantation, demonstrate potential in modulating disease progression. This review explores the evolving landscape of ALS diagnostics, highlighting advancements in biomarker development, such as neurofilament light chain and TAR DNA-binding protein-43 proteinopathy, which offer promising avenues for early detection and personalized interventions. Experimental models underscore the influence of microbial metabolites like short-chain fatty acids in neuroprotection and gut-brain communication. Additionally, the role of disease-modifying drugs such as riluzole, edaravone, and sodium phenylbutyrate-taurursodiol is discussed, emphasizing their impact on survival and quality of life. Future directions call for integrative approaches combining genetic, microbiological, and pharmacological insights to address the heterogeneity of ALS and develop effective therapies. This review underscores the critical need for multidisciplinary research to unravel the intricate mechanisms of ALS and improve patient outcomes.

[*] **Corresponding author Ajay Kumar:** Department of Pharmacology, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India; E-mail: ajaykumarbp@gmail.com

Ajay Kumar & Avinash Kumar (Eds.)

Keywords: Amyotrophic lateral sclerosis, Enteric nervous system, Gut-brain axis, Microbiota dysbiosis, Neurodegeneration.

INTRODUCTION

Amyotrophic Lateral Sclerosis (ALS), also referred to as Lou Gehrig's disease or Charcot disease, is a progressive and fatal neurodegenerative disorder characterized by the degeneration of both Upper Motor Neurons (UMNs) and Lower Motor Neurons (LMNs). This degeneration leads to muscle weakness, manifesting as muscle cramps, pain, restless leg syndrome, and eventual immobilization. ALS primarily affects motor neurons without involving the autonomic nervous system or sensory pathways [1]. The hallmark of ALS is the degeneration of LMNs in the spinal cord and brainstem and UMNs in the motor cortex, resulting in progressive denervation of voluntary muscles [2].

Charcot first identified the pathological features of ALS, including degeneration of corticospinal motor neurons and abnormal descending axons in the lateral spinal cord, coining the term “lateral sclerosis.” The term “amyotrophic” refers to spinal motor neuron degeneration, which causes muscle denervation and atrophy [3, 4]. ALS onset typically involves bulbar, limb, respiratory, or axial muscle weakness, with symptoms such as dysphagia, dysphonia, dysarthria, muscle cramps, fasciculations, and fatigue [5]. Disease progression varies among individuals, with approximately 25–30% of patients presenting early bulbar symptoms, such as dysphagia or masseter muscle weakness [6]. Patients often experience spasticity, secretory difficulties, and sleep-disordered breathing, necessitating ventilatory support to improve quality of life, though this cannot prevent eventual respiratory failure. Most patients succumb to neuromuscular respiratory complications within 2–3 years of symptom onset, although survival rates vary significantly [2, 6]. Sleep disruption is a common issue in ALS, arising from various etiologies, and is further compounded by the psychological burden of depression and existential fears, which frequently contribute to insomnia [7].

Approximately 50% of patients experience extra-motor symptoms, including behavioral and cognitive abnormalities. Between 35% and 40% of patients show mild cognitive or behavioural changes, while 10–15% develop Frontotemporal Dementia (FTD). FTD is characterized by atrophy in the frontal and anterior temporal lobes, leading to behavioral disturbances, impaired executive function, and/or language deficits. Given overlapping molecular pathways, ALS and FTD are now considered two extremes of a neurodegenerative spectrum [6].

Although the exact cause of ALS remains unknown, factors such as oxidative stress, genetic predisposition, excitotoxicity, autoimmune mechanisms, viral

infections, neurotrophic factor abnormalities, and environmental influences are implicated [8]. Approximately 10% of ALS cases are familial (FALS), linked to mutations in genes like *SOD1* (encoding Superoxide Dismutase 1), *C9orf72* (Chromosome 9 open reading frame 72), *FUS* (Fused in Sarcoma), *TARDBP* (encoding TAR DNA-binding protein 43, also known as TDP-43) and *TUBA4A*(encoding Tubulin alpha-4A), while 90% are sporadic (SALS) [6, 9, 10].

Currently, the diagnosis of ALS is based entirely on clinical criteria, as no reliable diagnostic tests or biomarkers are available. ALS diagnosis continues to rely on criteria such as the El Escorial, Revised El Escorial, Awaji, and, more recently, the Gold Coast criteria. These guidelines have evolved to address the variability in early symptoms and now incorporate tools like electromyography and fasciculation detection to identify subclinical motor neuron involvement. However, challenges remain, including the complexity of the diagnostic process, susceptibility to errors, and limited integration of emerging diagnostic technologies, such as neurophysiological and imaging biomarkers. The development of biomarkers for objectively assessing disease progression can significantly enhance the design of therapeutic trials and reduce associated costs [9, 11].

The gut-brain axis is critical for overall health and brain function. This bidirectional link involves the flow of impulses between the gut and the brain, affecting cognitive functions and emotions. A healthy gut microbiome can improve brain function by creating neuroactive chemicals such as short-chain fatty acids and serotonin, promoting mental health (Fig. **1**). Gut dysbiosis, on the other hand, can cause neuroinflammation, impairing mood and cognitive function. Recent research underscores the significance of the gut-brain axis in the pathogenesis of neurodegenerative diseases like ALS [8, 12]. Alterations in the gut microbiota composition and microbial translocation have been identified as potential risk factors for ALS, offering novel insights into disease mechanisms. The impact of gastrointestinal dysfunction in ALS, including changes in gut microbial communities, suggests a potential link between gut health and neurodegeneration. This emerging field may open new avenues for therapeutic interventions aimed at modulating the gut microbiome to slow or halt ALS progression [8, 12, 13].

CHAPTER 4

The Link Between Alzheimer's Disease and Gut Microbiome: A Growing Relationship

Prajapati Manisha Anil[1], Sandesh Kumar Pattanaik[2] and **Ashok Kumar Gupta[1,*]**

[1] *School of Pharmacy, Sharda University, Knowledge Park-3, Greater Noida, U.P-201306, India*

[2] *School of Pharmaceutical Sciences, Siksha 'O' Anusandhan Deemed to be University, Bhubaneswar, Odisha-751003, India*

Abstract: Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by impaired cognition and associated with the accumulation of amyloid-beta peptides in the brain. Researchers have reported that the wide range of microorganisms residing in the digestive tract is intricately linked to various physiological processes and diseases, including AD. The microbiota-gut-brain axis, a bidirectional communication system, plays a crucial role in the interaction between the gut and the brain. Alterations in the gut microbiota composition can lead to neuroinflammation, upregulate intestinal permeability, and result in altered neuroactive metabolites, contributing to AD. Understanding the relationship between the gut microbiota and AD may provide new insights into novel therapeutic strategies for this devastating and progressive disease. This chapter focuses on exploring the link between gut microbiota and AD, elucidating the mechanistic insights from pre-clinical to clinical studies, and exploring potential therapeutic interventions targeting gut microbiota to mitigate AD progression.

Keywords: Alzheimer's disease, Amyloid plaque, Blood-brain barrier, Gut microbiota, Inflammation, Neurodegenerative diseases.

INTRODUCTION

Alzheimer Diseases

Alzheimer's Disease (AD) is a prevalent kind of dementia that primarily affects older individuals, accounting for 60-70% of cases. It is characterized by the progressive degeneration of the brain. AD is distinguished by a progressive deterioration in behavior and cognitive function that significantly impacts individuals, their families, and society. AD symptoms occur one to two years after

* **Corresponding author Ashok Kumar Gupta:** School of Pharmacy, Sharda University, Knowledge Park-3, Greater Noida, U.P-201306, India; Tel: +7004278836; E-mail: ashokg195@gmail.com

Ajay Kumar & Avinash Kumar (Eds.)

the disease progresses. The incidence of AD in females and males is 41.9% and 33.6%, respectively, as reported in studies [1, 2]. According to the Alzheimer's Association, it is projected that by 2030, around 16 million individuals (about the population of New York), roughly equivalent to the population of New York, will be affected by AD [3]. The primary distinguishing characteristics of AD are the presence of amyloid beta and tau protein. The build-up of amyloid β at the synapses and the phosphorylation of tau protein result in the formation of neurofibrillary tangles, which lead to the loss of synaptic function and the development of AD. In addition to hallmarks, several additional factors contribute to AD, including neuroinflammation, oxidative stress, lipid metabolism, and cholinergic dysfunction. The accumulation of protein plaque triggers the activation of microglial and astrocyte cells, releasing pro-inflammatory cytokines such as TNF-α and IL-6. Therefore, the increase in cytokines leads to the death of neurons, resulting in a decline in cognitive function.

AD development is also attributed to cholinergic dysfunction. Acetylcholine (ChE) is the primary neurotransmitter that plays a crucial role in memory formation and acquiring new knowledge. Consequently, any decrease in ChE results in a deterioration of memory. The enzyme Acetylcholinesterase (AChE) is found in the post-synaptic neuron, where it breaks down ChE into choline and acetyl. In AD, the activity of AChE increases, leading to a reduction in the amount of ChE. This decrease in ChE contributes to cognitive deterioration. Lipid metabolism contributes to AD, accounting for 50% of the brain's weight. Lipids consist of fatty acids, cholesterol, sphingolipids, and phospholipids. All these play crucial roles in the brain. Sphingolipids and cholesterol play a pivotal role in signal transduction, the transfer of neurotransmitters, and the maintenance of synaptic plasticity. Fatty acids contribute 20% of the energy required by the brain. As a result, any disturbance in lipid metabolism may cause AD to develop due to decreased ATP, altered signal transduction, and loss of synaptic plasticity [2]. Currently, scientists have also investigated the correlation between gut microbiome and AD. The gut microbiome also plays a role in the development of AD. Disrupting beneficial microorganisms in the gut, such as *Bacteroidetes, Firmicutes, Actinobacteria,* and *Proteobacteria*, results in an imbalance that can contribute to several disorders, including AD. The relationship between AD and gut microbiota will be further explored.

Gut Microbiota

Gut microbiota refers to the diverse community of bacteria in the Gastrointestinal Tract (GIT). “Microbiome” is also used to refer to its association with protein and genome. An imbalance in the gut microbiota, known as dysbiosis, is associated with various disorders due to its influence on processes, metabolites, signaling

pathways, and neurotransmitters. Currently, gut microbiota is recognized as an essential part of the endocrine system, responsible for producing metabolites and regulating the GIT of the host (Fig. (**1**) [4]. GIT consists of almost 100 million microbiota. *Firmicutes, Actinobacteria, Bacteroidetes, Proteobacteria, Fusobacteria*, and *Verrucomicrobia* are a few types of gut microbiota. The two most prevalent microbiota are *Bacteroidetes* and *Firmicutes*. However, the complete makeup remains undisclosed. These are crucial for preserving the well-being of the host [5].



Fig. (1). The beneficial gut microbiota plays a crucial role in maintaining overall health by engaging in various mechanisms. They integrate with the intestinal barrier and produce beneficial metabolites such as Short-Chain Fatty Acids (SCFAs) and bile acids, which help prevent pathogen colonization of the intestinal lining, support digestive processes, and promote a balanced immune system. An unhealthy gut microbiota can disrupt immune system balance due to internal and external factors. When the intestinal barrier is compromised, harmful pathogens can enter the body and trigger the release of inflammatory compounds. Over time, this long-term pro-inflammatory response from the immune system can lead to the development of inflammatory conditions.

The microbiota is present from birth, but in a meager quantity. The increase begins after the birth. When a baby is delivered through the vagina, it comes into contact with several types of vaginal microbiota. This mechanism facilitates the growth and establishment of gut bacteria, like the microbiota in the mother's vagina. However, with cesarean delivery, microbiota growth is slow, and the composition varies. Microbiota development during the first year is characterized by a gradual pace and variances, which are believed to indicate the formation of

CHAPTER 5

Deciphering the Connection Between Gut Microbiota and Parkinson's Disease

Anmol Kumar[1,3], Anjali Gond[2], Noopur Verma[1] and **Ajay Kumar Gupta[1,*]**

[1] *School of Pharmaceutical Science (formerly University Institute of Pharmacy), Chhatrapati Shahu Ji Maharaj University (formerly Kanpur University) Campus, Kanpur 208024, India*

[2] *Department of Biotechnology, Institute of Applied Science and Humanities, GLA University Mathura, 281406, Uttar Pradesh, India*

[3] *Krishna Institute of Pharmacy and Sciences, Kanpur, India*

Abstract: Emerging studies in neurogastroenterology have recently illuminated the complicated connection between gut microbiota and Parkinson's disease, which is the second most common progressive neurodegenerative disorder. The gut microbiota is a community of symbiotic gut flora and has an important role in human health and disease. The dysfunction with gut microflora is known as 'gut dysbiosis' and is characterized by an increase in gut-derived proinflammatory microbes, which increase the opportunist mediators such as lipopolysaccharides and H_2S that cause inflammation in the gut and increase gut permeability, while concurrently decreasing certain anti-inflammatory compounds, such as short-chain fatty acids. Gut dysbiosis also plays a significant role in the development of neurodegenerative disorders, including Parkinson's Disease (PD). Gut dysbiosis-mediated inflammation leads to the aggregation of α-synuclein and neuroinflammation mediators, which further spread to the CNS *via* the connection between the microbiota-gut-brain axis, and promotes the accumulation of α-synuclein in the SNpc. Neuroinflammation and oxidative stress lead to the destruction of dopaminergic neurons, ultimately leading to PD. The intestinal microbiome presents a potential avenue for both diagnosis and treatment of Parkinson's disease. This can be modulated through various interventions, including treatment with probiotics, psychobiotics, prebiotics, synbiotics, and postbiotics, as well as fecal microbiota transplantation and dietary adjustments.

Keywords: Gut microbiota, Gut dysbiosis, Microbiota-Gut-brain axis, Neurogastroenterology, Parkinson's disease, SNpc.

[*] **Corresponding author Ajay Kumar Gupta:** School of Pharmaceutical Science (formerly University Institute of Pharmacy), Chhatrapati Shahu Ji Maharaj University (formerly Kanpur University) campus, Kanpur 208024, India; E-mail: ajaykumargupta@csjmu.ac.in

INTRODUCTION

Gut microbiota is a scientific term that refers to a vast variety of microorganisms residing in the Gastrointestinal (GI) tract and playing an important role in maintaining and managing gut health. It includes microorganisms like bacteria, viruses, and fungi. The scientists Louis Pasteur and Élie Metchnikoff first recognized the importance of microorganisms in digestion and disease prevention during the late 19th and early 20th centuries. Initially referred to as 'microflora,' the term was later replaced by 'microbiota' as scientific understanding expanded to encompass a broader range of organisms. By the late 20th century, advancements in DNA sequencing enabled more detailed studies on these microbial communities [1, 2]. The Human Microbiome Project, launched in 2007, established 'gut microbiota' as a critical term, highlighting the essential role of the trillions of gut microorganisms in maintaining overall health through their involvement in digestion, absorption of nutrients, immune modulation, and metabolic processes. They possess a diverse array of metabolic genes that help in the breakdown/fermentation of complex carbohydrates and fibres into Short-Chain Fatty Acids (SCFAs) [3]. The gut microbiota plays a crucial role in maintaining the integrity of both the blood-brain barrier and the gut barrier, acting as a shield to prevent harmful bacteria from entering the body. It is also fundamental to the development and proper functioning of the immune system. By secreting various antimicrobial compounds and aiding in the maturation of the intestinal mucosa, the microbiota enhances the body's ability to respond to pathogens. When this delicate balance is disrupted, a condition known as dysbiosis, it can lead to a range of diseases. Maintaining a healthy and diverse gut microbiota is vital for overall well-being, as imbalances are linked to health issues such as obesity and chronic inflammatory conditions like Inflammatory Bowel Disease (IBD). The health of the brain is also affected by the microbiota population, which leads to the evolution of neurological disorders such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease. Research findings suggest that changes in the variety and population of gut microbiota influence the production and levels of neurotransmitters like serotonin, dopamine, Gamma-Aminobutyric Acid (GABA), and other metabolites that play vital roles in brain function and mood regulation [4]. The gut-brain axis forms a vital link between the Central Nervous System (CNS) and the Enteric Nervous System (ENS), a component of the Autonomic Nervous System (ANS) located in the Gastrointestinal Tract (GIT). This intricate connection plays a significant role in maintaining brain health and operates through various pathways, including neural, hormonal, immune, and microbial mechanisms. A key player in this interaction is the vagus nerve, which acts as a communication bridge, transmitting signals between the gut and the brain to influence both physical and mental processes [5]. Hormones such as cortisol and ghrelin mediate hormonal pathways, while

immune molecules like cytokines impact brain function as part of immune-related mechanisms. Additionally, metabolites produced by gut microbiota further contribute to this bidirectional communication, highlighting the complexity and importance of this gut-brain relationship [6]. The gut-brain axis plays a crucial role in regulating various physiological functions, such as body temperature, as well as psychological processes, including mood, cognition, and immune system activity. This chapter delves into the vital connection between gut microbiota and Parkinson's Disease (PD), a debilitating condition that ranks as the second most prevalent neurodegenerative disorder, affecting millions of people worldwide. It explores how this intricate relationship influences the progression and management of PD, offering insights into its broader implications for health and disease [5]. Parkinson's Disease (PD) is a chronic neurodegenerative disorder that affects multiple body systems, with akinesia being one of its primary characteristics. Patients with PD often exhibit distinctive motor symptoms, such as resting tremors, muscle rigidity, and gait abnormalities. Beyond these, non-motor symptoms are also common, including a diminished sense of smell, sleep disturbances, depression, and Gastrointestinal (GI) issues. A significant connection between PD and gut health has been identified, particularly regarding the gut microbiota. Research indicates that up to 80% of individuals with PD experience GI and digestive system problems, often leading to conditions like gastroparesis. Notably, constipation frequently appears before the onset of motor symptoms, serving as a critical early indicator for diagnosing PD. This highlights the importance of gut health in understanding and managing the disease [7]. Neuropathologically, PD is mainly marked by the destruction of the dopamine-producing neurons in the brain region known as the Substantia Nigra pars compacta (SNpc). The development of abnormal protein clumps formed by the misfolding of α-synuclein proteins is known as Lewy neurites (abnormal neurites in diseased neurons, containing granular material and abnormal α-synuclein filaments), which are a significant constituent in the causation and pathogenesis of the disease [6]. The enteric system is a hub of microorganisms, known as the gut microbiota, which plays a crucial role in maintaining a healthy gut and nervous system. Eubiosis is defined as the balanced population of microbiota that impacts the healthy composition and structure of the microbial community. Certain factors that can influence the balance of gut microbiota are age, sex, lifestyle, geographic location, and diet. However, when this balance is disrupted, a condition known as dysbiosis can occur, which leads to the development of various diseases like Parkinson’s disease, a key focus of this chapter (8).

Neurogastroenterology and its Relevance to PD

Neurogastroenterology is a subspecialty within gastroenterology that focuses on the complex connection between the nervous system and the GI tract, which

CHAPTER 6

The Gut Microbiota's Impact on the Emergence and Development of Neurodegenerative Diseases

Mohd Qasid Lari[1], Astik Manju Ashesh[1], Avinash Kumar[3], Dileep Kumar[1] and **Ajay Kumar[1,*]**

[1] *Department of Pharmacology, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India*

[2] *Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal-576104, Karnataka, India*

[3] *Department of Pharmaceutics, Sardar Patel College of Pharmacy, Gorakhpur, U.P-273013, India*

Abstract: An intricate community of microorganisms living in the gastrointestinal tract, known as the gut microbiota, has come to be recognised as a vital component of human health, impacting a range of physiological functions such as metabolism and immunological response. The possible influence of gut microbiota on the development and course of neurodegenerative illnesses, including multiple sclerosis, Parkinson's disease, and Alzheimer's disease, has been brought to light by recent research. Dysbiosis, defined by alterations in the makeup of the gut microbiota, has been connected to the emergence of neurodegenerative illnesses. There are several pathways that facilitate bilateral interaction between the GIT and the brain, including metabolites produced by gut bacteria and neurotransmitters. In addition, research is being done on probiotics and dietary modifications as possible therapeutic approaches to rebalance microbes and slow the progression of neurodegenerative diseases.

This chapter investigates the complex connection between human health and gut bacteria, particularly focusing on how it influences neurodegenerative illnesses. The composition of the gut microbiome is emphasised, as is how it affects brain function through the gut-brain axis. This chapter also includes intriguing preclinical and clinical data on prospective treatment techniques that target the gut microbiota, such as antibiotics, probiotics, and prebiotics, along with fecal microbiota transplantation. All things considered, this work highlights the importance of gut microbiota in relation to neurodegenerative diseases and the necessity of comprehending and treating the gut-brain axis in future therapeutic approaches.

Keywords: Alzheimer's disease, Antibiotics, Neurodegenerative disease, Multiple sclerosis, Probiotics, Parkinson's disease.

[*] **Corresponding author Ajay Kumar:** Department of Pharmacology, Sardar Patel College of Pharmacy, Gorakhpur, UP-273013, India; E-mail: ajaykumarbp@gmail.com

Ajay Kumar & Avinash Kumar (Eds.)

INTRODUCTION

A community that lives permanently in the gastrointestinal tract (GIT) is known as the gut microbiota (GM). The GM is responsible for overall health and maintaining intestinal homeostasis. Bacteria, viruses, fungi, and protozoa are among the several microorganisms classified as GM. These organisms collaborate in breaking down food, produce nutrients, and assist the immune system [1]. Microbes are abundant on the skin, as well as in the respiratory, gastrointestinal, and genitourinary systems. The GIT is the organ with the highest density of colonisation; it is estimated that over 70% of all bacteria in the human body are found in the colon alone. Following birth, the aerobic bacteria that dominated prenatal and postnatal development change. During the first several weeks of life, the microbiota develops into a diverse microbial community dominated by anaerobes [2]. The gut microbiota is mostly composed of strict anaerobes.

The human gut microbiota is dominated by just two bacterial species—*Bacteroidetes* and *Firmicutes*—despite the fact that over 50 species have been identified to date. *Proteobacteria*, *Verrucomicrobia*, *Actinobacteria*, *Fusobacteria*, and *Cyanobacteria* are present in smaller amounts [3].

Neurodegenerative disorders (NDs) are characterized by the progressive degradation of the brain's anatomy and physiology, leading to a loss in cognitive and motor capacities, which include Huntington's disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS). Human mental and physical health are seriously threatened by the rising morbidity linked to these illnesses [4]. The importance of the gut-brain axis (GBA) in the development and course of NDs has been brought to light by recent studies. The gut microbiota plays an important role in the GBA, a two-way communication system linking the gut and the brain [5].

AD is characterised by amyloid beta (Aβ) plaques and neurofibrillary tangles, which may be caused by disruptions along the brain-gut-microbiota axis [6]. It is widely accepted that the microbiota in the gut serves a crucial role in the pathogenesis of AD by regulating neuroinflammation and neurodegeneration through immune activation and systemic inflammation [7, 8]. Similarly, gut dysbiosis has also been implicated in the pathogenesis of PD, where it can trigger intestinal inflammation, alter gut-brain communication, and lead to neuroinflammation and neurodegeneration [9]. Through a variety of immunological, neuronal, and metabolic pathways, the gut microbiota has also been linked to other NDs, such as ALS and HD, where it may affect disease susceptibility and progression [10, 11].

Understanding the involvement of the gut microbiota in NDs is crucial for developing innovative interventions and clinical therapies. Antibiotics and other medications can be utilized to target particular bacterial species, while probiotics and transplantation of fecal microbiota can be used to maintain an optimal gut microbiota [5]. Furthermore, dietary changes like cutting back on ultra-processed foods can lessen the negative effects of gut dysbiosis on neurodegeneration and cognitive decline [12].

Thus, an analysis of the GBA and the function of the gut microbiota in NDs can shed light on the causes and progression of these conditions. This information can lead to better clinical interventions and treatments, which will ultimately improve the quality of life for those with neurodegenerative diseases.

GUT MICROBIOTA

A diverse range of dynamic microorganisms that make up the gut microbiota form a symbiotic relationship with the human host. The gut microbiota's metabolic activities and interactions influence typical physiological processes and the host's susceptibility to sickness [13]. The variation and individual differences at the bacterial strain level are caused by variations in the gut's pH, immunological factors, and digestive enzymes [5]. Furthermore, every person possesses a unique microbial community that leads to the establishment of a stable and resilient condition [14]. Bacteroidetes and Firmicutes dominate the adult gut mucosa, while Verrucomicrobia, Proteobacteria, and Actinobacteria are relatively low [15].

The gut microbiota plays an important role in human health by producing microbial components such as vitamins, vital amino acids, and lipids [16 - 18]. These substances might impact physiological processes such as the gut barrier, nutritional metabolism, immunological response, and neurological growth associated with aging through neuronal, endocrine, and immune signaling pathways involved in the GBA [19 - 21].

MECHANISMS DRIVING THE IMPACT OF GUT MICROBIOTA ON NEURODEGENERATION

The gut microbiota has been progressively linked to neurodegenerative illnesses and has a vital role in affecting brain health *via* the gut-brain axis, a complex two-way communication network. It is found that the gut microbiota may be responsible for different types of neurodegenerative disease through a number of mechanisms (Fig. **1**).

CHAPTER 7

The Gut-Brain Axis in Irritable Bowel Syndrome

Manisha Kawadkar[1,*], Deepika Devnani[1], Avinash Kumar[2], Dimak Chand Sahu[1] and **Arvind Kumar Singh Chandel[3]**

[1] *School of Pharmacy, GH Raisoni University, Saikheda, Pandhurna (M.P), India*

[2] *Department of Pharmaceutics, Sardar Patel College of Pharmacy, Gorakhpur-273013, India*

[3] *School of Engineering, University of Limerick, Limerick V94 T9PX, Ireland*

Abstract: The Gut-Brain Axis, or GBA, features significantly in the pathophysiology of Irritable Bowel Syndrome. This common functional gastrointestinal disorder is characterised by recurrent abdominal pain, often with bloating and distension, and by irregular bowel habits. This complex, bidirectional communication network links the CNS, ENS, immune responses, hormonal signals, and gut microbiota. Such a balance within the GBA causes increased sensitivity in the visceral system, motility changes, and enhanced susceptibility to psychological stressors. This chapter discusses the underpinning mechanisms of gut-brain axis dysregulation in IBS, including the interaction between the nervous and immune systems, the role of gut microbiota in intestinal homeostasis, and the effect of stress/psychological factors on triggering exacerbation of symptoms of IBS. It also discusses therapeutic approaches targeting the GBA itself, such as probiotics, nutrition interventions, psychotropic therapy, and cognitive-behavior therapy. Unfolding key insights into the etiology of IBS, an in-depth understanding of the complex dynamics of the GBA provides innovative approaches for improving symptom management and enhancing quality of life for patients.

Keywords: Enteric Nervous System (ENS), Gut-Brain Axis (GBA), Gut Microbiota, Irritable Bowel Syndrome (IBS), Low-grade inflammation, Motility disorders, Neuroimmune interactions, Probiotics, Psychological stress, Visceral hypersensitivity.

INTRODUCTION

Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal disorder that shows the complex interrelationship of the gastrointestinal system and the central nervous system [1]. Unlike most other gastrointestinal diseases, IBS is characterized by functional abnormalities rather than structural anomalies with

[*] **Corresponding author Manisha Kawadkar:** School of Pharmacy, GH Raisoni University, Saikheda, Pandhurna (M.P), India; E-mail: manishakawadkar@gmail.com

symptoms such as abdominal discomfort, bloating, and changes in bowel habit [2]. Recently, it has been made clearer that the gut-brain axis is a two-way communication pathway that links the Central Nervous System (CNS) with the Enteric Nervous System (ENS) [3].

The gut-brain axis integrates neural, hormonal, and immune pathways to sustain gastrointestinal homeostasis. In IBS, this pathway is usually disrupted, manifesting as increased visceral sensitivity, altered motility, and dysregulation of the immune system. Psychological factors, such as stress and anxiety, also influence this axis, thus exacerbating the symptoms of IBS. More recent studies suggest that gut microbiota may be an important mediator in this relationship, meaning that differences in microbial communities can have a profound impact on both gastrointestinal function and mental well-being [4 - 7].

This chapter goes further into the intricacies of the gut-brain axis in IBS, where it explores mechanisms that might explain gut-brain dysregulation, psychological stressors' effects, and the therapeutic potential of targeting this axis with diet, probiotics, pharmacological agents, and psychological interventions [8]. It is vital for better management of IBS and improved outcomes to understand the gut-brain connection.

The Gut-Brain Axis: Structure and Function

The Gut-Brain Axis (GBA) is an example of two-way communication between the gastrointestinal (GI) tract and the Central Nervous System (CNS). The system is highly effective, enabling the brain to interact with the gut and vice versa, involving numerous physiological and psychological activities. Central to this communication is the interaction between the CNS and the Enteric Nervous System (ENS), the intrinsic neural network within the gut [9, 10].

Central Nervous System (CNS)

The brain and spinal cord make up the CNS. It processes and interprets sensory input from all parts of the body, including the gut. It is responsible for controlling many physiological functions like gut motility, digestion, and immune responses through descending pathways acting on the ENS [9].

Major Functions of CNS in the Gut-Brain Axis

1. **Motility and Digestive Regulation:** The CNS controls **voluntary** and **involuntary** aspects of **gut motility**. It influences the **speed** and **efficiency** of food transit through the digestive system.
2. **Pain and Sensory Perception:** The brain processes sensory signals from the

gut, contributing to **visceral pain** or discomfort.
3. **Psychological Impact on Gut Function:** Stress, anxiety, **and** depression **can trigger or exacerbate gastrointestinal symptoms.**
4. **Neurotransmitter Modulation:** The brain regulates the release of several neurotransmitters such as **serotonin**, **dopamine**, and **Corticotropin-Releasing Hormone (CRH)**, which have widespread effects on both the CNS and the ENS, influencing mood, motility, and pain perception [10].

ENTERIC NERVOUS SYSTEM (ENS)

Generally, the ENS or Enteric Nervous System, which many people call the second brain, has an extensive neuronal network within the walls of the entire gastrointestinal tract. It has approximately 100 million neurons, more than the spinal cord, and can function autonomously from the CNS to manage a variety of processes within the gut [11].

Functions of ENS

1. **Autonomous Gut Regulation:** Thus, this framework is able to regulate the gut motility, secretion, blood flow, and intestinal permeability without the CNS. It can also deal with all signals that are related to food movement, secretion of digestive enzymes, and absorption of nutrients.
2. **Complex Neural Reflexes:** The ENS is involved in **local reflexes**, such as the **peristaltic reflex**, which coordinates the rhythmic contractions of the intestines for **propelling** food through the GI tract. It also regulates **intestinal secretions** to aid digestion and **fluid absorption**.
3. **Communication with the CNS *via* the Vagus Nerve:** Despite its autonomy, the ENS communicates with the CNS *via* the **vagus nerve**, the main **bidirectional pathway** between the brain and gut.
4. **Microbial Influence:** The ENS is heavily influenced by the **gut microbiota** (the trillions of microorganisms living in the digestive tract).

Bidirectional Communication: CNS ↔ ENS

The **CNS-ENS interaction** is bidirectional, meaning the gut and brain communicate in both directions:

Descending Pathways from the CNS to the ENS

Brain-to-Gut Signaling: The brain communicates with the ENS using descending pathways, which adjust gut function. These signals induce changes in motility, secretion, and blood flow in the gut. Stress and emotions relay signals that travel *via* the hypothalamus (where stress response occurs) to the gut, resulting in possible changes in gut motility, secretion, and overall function, which is the basis

CHAPTER 8

Therapeutic Strategies for Neurodegenerative Diseases *via* Gut Microbiota Modification

Chitrali Talele[1], Chintan Aundhia[1], Dipali Talele[2,*], Manisha Lalan[3], A.K. Seth[1] and **Mamta Kumari[1]**

[1] Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, 391760, India

[2] School of Pharmacy, Vishwakarma University, Survey No 2,3,4 Laxmi Nagar, Kondhwa, Budruk, Pune 411048, India

[3] Department of Pharmaceutics, Parul University of Pharmacy & Research, Faculty of Pharmacy, Parul University, Limda, Waghodia-391760, Vadodara, Gujarat, India

Abstract: The gut microbiome has been the subject of much investigation because of its biological diversity and possible role in spreading diseases outside the gastrointestinal tract. Understanding the gut-brain axis and the peculiar interplay between the neurological and GI systems has garnered much attention recently. Numerous studies have also demonstrated how the gut microbiota may contribute to the severity of a variety of neurological conditions, including neurodegenerative diseases. Patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis were shown to have different microbiome profiles and dysbiosis.

This chapter discusses several methods for restoring the balance of the gut microbiome in the particular context of treating neurodegenerative illnesses, including faecal microbiota transplantation, antibiotic therapy, and psychobiotic use. Current research and clinical trials show that, despite the enormous potential for preventive or therapeutic effects of gut microbiome modification, there are still many interconnected elements of the gut-brain axis at work. As a result, more study is required to identify the specific microbiome factors that may be able to lessen neurodegenerative symptoms.

Keywords: Biological diversity, Clinical trials, Gut microbiome balance, Gut microbiome, Neurodegenerative diseases, Therapeutic effects.

[*] **Corresponding author Dipali Talele:** School of Pharmacy, Vishwakarma University, Survey No 2,3,4 Laxmi Nagar, Kondhwa, Budruk, Pune 411048, India; E-mail: dipalitalele93@gmail.com

Ajay Kumar & Avinash Kumar (Eds.)

INTRODUCTION

Clarifying the relationship between the gut microbiome and various organs is becoming more and more popular. Research on gut microbiome manipulation emerged as a result of the GI tract's microbiome's demonstrated ability to influence neurological and psychological features [1, 2]. This is the first method of manipulating the gut microbiome. Psychobiotics are described as digestible live organisms that can produce health advantages in neuropsychological situations [3]. Faecal microbiota transplantation (FMT) and antibiotic therapy are additional methods for eliminating harmful pathogens. While many studies have been conducted on the emotional impact of gut microbiota, there are relatively few that examine the applicability of manipulating gut microbiota to treat neurodegenerative illnesses, which are more complex and debilitating. Neurodegenerative diseases, also referred to as disorders that cause the loss of motor skills, cognitive abilities, and even memory, have a variety of risk factors that can build up throughout a lifetime. These risk factors include genetic predispositions, oxidative stress, or physiological trauma [4, 5]. Many investigations into neurodegenerative diseases have produced a multitude of knowledge on the causes of these problems and potential therapies. In current times, there has been a growing concern within the technical community concerning the prevention of neurodegeneration as well as the mitigation of its harm. Induction of neuroprotection [6, 7], resistance to key mixtures known to produce neuronal degeneration [8, 9], genetic modification through gene transfer [10], or genome editing tools are some potential successes in the field of neurodegeneration prevention [11].

Alterations to the gut microbiota present a prophylactic strategy that needs to be considered an additional tool in the toolbox for combating neurodegenerative illnesses prior to the onset or swift advancement of the condition. Numerous studies have found links between gut and brain health, despite the fact that this arena of study is in its initial stages. Some of these studies even hint at the possibility of using this field to prevent or treat dementia.

The existence of dysbiosis in the digestive tract of humans is linked to neurodegenerative disorders as a cause or result. The goal of the chapter is to emphasize the importance of gut microbiota alteration against indications and/or reasons of these diseases. This would raise awareness of the role dysbiosis plays in neurodegeneration and highlight the importance of taking the gut microbiota into account when looking for new molecular markers of neurodegenerative illnesses.

IMPORTANCE OF GUT-BRAIN COMMUNICATION AND DYSBIOSIS

Numerous variables, including bidirectional or potentially multifaceted interaction by neurotransmitters and other intermediates amongst the neurological system, gut microbiota, and immune response, may be responsible for the seemingly strange gut-brain communication [12]. An in vivo study that showed the absence of proliferation in mouse models with antibiotic-induced intestinal microbiota removal demonstrated the real neurological effects of the gut microbiota. The function of Ly6Chi-tagged monocytes as a messenger between the stomach and the brain was also documented in this work [13]. Neuropeptide Y synthesis was shown to be harshly impaired in a study that investigated cognitive loss caused by intestinal dysbacteriosis in vivo [14]. Dysbacteriosis has also been shown in medical cases to diminish physical and mental balance, given the multiple levels of connection that exist among not only the microbiome in our gut and neurotransmitters, but also the cells proficient in circulating these gut-brain indications [15, 16]. However, it has been demonstrated in a promising way that diet-based restoration of microbial composition can reverse such abnormalities [17]. Enterochromaffin cells (EC), for example, are new participants in the gut-brain axis that have been identified by recent research. Although intestinal organoids are an uncommon cell type inside the intestinal epithelia, their research has helped to adequately explain the biophysical and molecular activities of EC, as demonstrated by Bellono *et al*.'s study [18]. The serotonergic EC directly interacts with the gut microbiota and afferent nerve fiber connections to create the body's essential neurotransmitter, serotonin (5-HT). In germ-free (GF) in vivo mouse models, the spore-forming microbiota (*e.g*., Clostridium spp.) was shown to reestablish 5-HT levels by regulating the enzyme tryptophan hydroxylase and the 5-HT transporter SLC6A4 in the context of ECs [19]. Additionally, in vitro research employing a human EC cell model revealed that the synthesis of short-chain fatty acids (SCFAs) facilitated the modulatory activity of microbiota intervention [20]. The functions of the vagus nerve, which may further support this relationship and specify that a healthy microbiota is indicated when the vagus nerve is activated by acetylcholine nicotinic receptors [21], are additional intriguing data. Signal relay is the responsibility of neurochemicals such as gamma-aminobutyric acid (GABA) and brain-derived neurotrophic factor (BDNF), which have been practically associated with the spread of Vagal nerve stimulation when the probiotics *Lactobacillus rhamnosu*s and *Bifidobacterium longum* are consumed [22, 23]. The numerous studies that attempt to simplify the mechanics of the gut-brain axis include the intriguing connections among the gut microbiota and the nervous system regions mentioned in this chapter. For instance, stress is known to influence the health of the gut microbiota by interacting with several inflammatory cytokine cascades [24]. Further evidence of its clinical significance comes from psychobiotic studies' observation of

CHAPTER 9

Exploring the Role of Probiotics, Prebiotics, and Symbiotics in The Management of Neurodegenerative Diseases

Chintan Aundhia[1,*], Ghanshyam Parmar[1], Chitrali Talele[1], Piyush Kumar Sadhu[1] and **A.K. Seth[1]**

[1] *Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat-391760, India*

Abstract: This chapter examines the possible therapeutic advantages of microbiome-focused treatments in neurodegenerative conditions such as Alzheimer's, Parkinson's, and Huntington's illnesses. Recent studies reveal that the composition of gut microbiota plays a crucial role in brain health by affecting the gut-brain axis. This implies that altering the composition of gut microbiota might potentially affect the course and symptoms of neurodegenerative diseases. This chapter presents a thorough examination of how probiotics, prebiotics, and symbiotics impact the gut-brain axis, with a specific emphasis on their effects on neuroinflammation, oxidative stress, and neuroprotection. The forms and origins of these therapies, their metabolic pathways, and the most recent results from preclinical and clinical research are some of the important topics addressed. The chapter also examines the challenges and future directions in this area, emphasising the promise of microbiome-based treatments to enhance the quality of life for people with neurodegenerative disorders.

Keywords: Gut-brain axis, Gut microbiota, Neurodegenerative diseases, Neuroinflammation, Oxidative stress, Probiotics, Prebiotics, Symbiotics.

INTRODUCTION

Overview of Neurodegenerative Diseases

Neurodegenerative diseases comprise a broad category of disorders that are typically characterized by the progressive degeneration of the neuronal structure,

[*] **Corresponding author Chintan Aundhia:** Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat-391760, India; E-mail: aundhia@gmail.com

Ajay Kumar & Avinash Kumar (Eds.)

thereby impacting their function [1]. This degeneration often arises from the accumulation of cellular and molecular damage, mostly impacting neurons, which possess restricted regenerating capability. Common neurodegenerative disorders include Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's, Disease, and Amyotrophic Lateral Sclerosis (ALS) [2]. Although each disease is associated with unique pathophysiological characteristics and individual symptoms, several conditions have comparable mechanisms, including neuroinflammation, oxidative stress, protein misfolding, and excitotoxicity [3].

Neurodegenerative disorders pathophysiologically affect neurons in certain brain areas, leading to various cognitive and movement impairments. AD is marked by the formation of amyloid-β (Aβ) plaques and neurofibrillary tangles made up of hyperphosphorylated tau protein. PD affects the dopaminergic neurons, whereas Huntington's disease causes neuronal death primarily in the striatum. Similarly, Amyotrophic Lateral Sclerosis is a motor neuron disease marked by the progressive loss of both upper and lower motor neurons, manifesting in muscle weakness, atrophy, and ultimately, respiratory failure [4].

Diverse pathogenic processes cause various diseases. Protein misfolding and aggregation are critical factors, with misfolded proteins such as Aβ and tau in Alzheimer's disease, α-synuclein in Parkinson's disease, and mutant huntingtin in Huntington's disease associated with cellular toxicity, compromised protein clearance, and altered cellular homeostasis [5]. Oxidative stress and mitochondrial dysfunction are crucial, as the overproduction of reactive oxygen species (ROS) and reactive nitrogen species (RNS) results in damage to cellular lipids, proteins, and DNA. Neurons, characterized by elevated metabolic requirements, are more vulnerable to oxidative injury and mitochondrial impairment [6].

Excitotoxicity is a pathogenic process that arises from the overactivation of neurotransmitters such as glutamate, causing calcium overload in neurons and triggering enzymatic cascades. This can eventually lead to cell death [7]. Chronic neuroinflammation is induced by activated microglia and astrocytes. Although it is initially beneficial, prolonged inflammation intensifies neuronal injury and accelerates disease advancement [8].

Treatments for neurodegenerative diseases are restricted to symptom alleviation and cannot prevent disease progression. Acetylcholinesterase inhibitors are commonly used for AD, dopamine replacement therapy for PD, and riluzole for ALS. Thus, research into alternative therapeutic strategies, including gut microbiome modulation, is gaining considerable attention as a potential avenue for disease intervention [9].

The Gut-Brain Axis

The gut-brain axis is a sophisticated, bidirectional communication network connecting the gastrointestinal tract with the central nervous system. It integrates the neural, hormonal, immune, and metabolic pathways, facilitating dynamic interactions between gut microbes, gut physiology, and brain function [10]. The gut-brain axis has, in recent years, become a fundamental component in the understanding of the pathology of neurodegenerative diseases through the understanding of microbiota changes within the gastrointestinal tract and its correlation to disorders of the central nervous system [11].

It functions through several mechanisms. Vagal nerves are primarily responsible for sending information through the gut to the brain, concerned with the gut's physiologic status, to the hypothalamus, amygdala, and other components in the brain stem that are mainly concerned with autonomic regulation and emotional processing. The gut endocrine system allows gut bacteria to influence hormone release, such as GLP-1, ghrelin, and leptin, which in turn control the brain and its actions. Through immune mediators, the gut microbiota communicates with gut-associated lymphoid tissue, which modulates CNS inflammation and, thereafter, contributes to neurodegeneration [12]. Chronic inflammation, accompanied by increased cytokines and chemokines, disrupts the BBB and permits the immigration of immune cells and microbial products into the CNS. They found that metabolic pathways are initiated when the gut microbiota synthesizes SCFAs, including butyrate, propionate, and acetate, tryptophan metabolites, and bile acids that actively modulate the CNS. These molecules regulate inflammation, thereby maintaining the BBB integrity, and neurotransmitter synthesis [13].

Alterations in the composition of the microbiota have been described in association with neurodegenerative diseases. It has been established that patients with neurodegenerative diseases have an unhealthy balance of gut bacteria, like anti-inflammatory Faecalibacterium and high levels of Pro-inflammatory Proteobacteria, which are related to PD [14]. Also, skewed ratios of Firmicutes and Bacteroidetes have been associated with cognitive decline and an AD profile. At the cellular level, the gut microbiota is able to synthesize amyloid-like proteins, lipopolysaccharides (LPS), and other microbial metabolites influencing neurodegeneration [15]. Amyloid proteins are produced by certain gut bacteria; therefore, they could be involved in the clearance of amyloid in the CNS and promotion of diseases such as AD. Similarly, LPS, an endotoxin derived from Gram-negative bacteria, amplifies neuroinflammation, disrupts the BBB, and triggers systemic inflammation [16].

CHAPTER 10

Diet And Lifestyle Management in Nurturing the Gut-Brain Axis

Sandhya Vasanth[1,*], Sindhu Priya E. S.[2], Mohammed Gulzar Ahmed[1], Sneh Priya[3] and **Alima Misiriya[1]**

[1] *Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to Be University), Mangalore, 575018, Karnataka, India*

[2] *Department of Pharmacology, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to Be University), Mangalore, 575018, Karnataka, India*

[3] *Department of Pharmaceutics, N.G.S.M Institute of Pharmaceutical Science, Nitte (Deemed to Be University), Mangalore, 575018, Karnataka, India*

Abstract: The gastrointestinal tract (GIT) is not just a digestive system, but a complex ecosystem that houses Gut Microbiomes (GMs), which play a pivotal role in food digestion, nutrient conversion, and neurotransmitter synthesis. Diet and lifestyle are essential components in the composition and function of the gut microbiota, and they impact the Central Nervous System's (CNS's) functioning. The gut-brain axis is a two-way link between the GIT and the CNS. The physiology of the GIT is to digest the food and liquid intake, and CNS physiology controls the autonomous and peripheral nervous systems (voluntary and involuntary movement of the human body). A diet rich in high-fibre, protein, essential lipids, and nutrients from whole grains, vegetables, and fruits can create a favourable environment in the gastrointestinal tract for beneficial gut microbiomes. The diet includes high carbohydrate and sugar intake, fat, junk food, stress, and a sedentary lifestyle that alters the intestinal barrier, promotes the growth of GMs, and results in disorders such as inflammation in the GIT, bowel syndrome, dysbiosis, and cognitive impairment. The research studies have proved the effectiveness of protection of the natural flora of GIT through intermittent fasting, exercise, a balanced diet, sleep, and meditation, and the results showed that it boosts the environment for microbial diversity, short-chain fatty acids, autophagy, and production of a protein called Brain-Derived Neurotrophic Factor (BDNF).

Keywords: Gut-Brain Axis (GBA), High fibre, Gut microbiomes (GMs), Diet, Physical activities.

[*] **Corresponding author Sandhya Vasanth:** Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to Be University), Mangalore, 575018, Karnataka, India;
E-mail: sandhyav@yenepoya.edu.in

Ajay Kumar & Avinash Kumar (Eds.)

INTRODUCTION

Each part of the human body consists of various microorganisms, including bacteria, viruses, archaea, lower and higher eukaryotes, and fungi, which are vital in building the body's immune system. There are thousands of vast species, primarily located in the gut. The present research has proved the importance of the multiple roles of these gut microorganisms in human health and well-being, both physically and mentally. They also control the Central Nervous System (CNS), play a crucial role in sensory control and both voluntary and involuntary actions, and regulate the person's motion with the help of nerve cells. Gut Microbes (GM) play a vital role in synthesising the chemicals or nutrients required by neurons, with the help of the human diet. Over the past thirty years, studies have consistently demonstrated that gut microbiota have a significant impact on a person’s neurological health. Nutrition, one of the most critical factors, is a key determinant of gut microbiota formation, as it simultaneously alters the diversity and number of bacteria, as well as the metabolic profile of bacterial composition.

Additionally, attention has shifted towards the role of diet patterns in maintaining optimal psychological health [1]. Psychobiotics are external factors that modulate the microbiota, influencing health, particularly mental health, through bacterial mechanisms, including prebiotics, probiotics, and dietary factors. A more modern intake, characterised by highly processed, fried, and sugar-filled foods, and a lower intake of whole-food biotaome source crops rich in fibre and polyphenols, leads to the loss of valuable beneficial microbes and the rise of potential pathogens, all creating a health threat in humans [2]. Incorporating healthy food consumption with improving or changing the communication pattern between the gut and brain is one aspect highlighted in the prevention and management of common mental afflictions. Newer studies investigate the impact of adding specific individual foods, such as prebiotic-rich fruits, vegetables, and tubers, on gut microbiomes and host interconnections, with some encouraging results. It should be noted, however, that while these approaches are essential for increasing knowledge regarding the impact of particular foods on human microbiota and health and may help in the discovery of new functional foods, it must be appreciated that humans mainly eat a variety of food categories at every meal [3]. As a result, studies on single foods may overlook possible synergistic effects of food on general health and well-being, as well as the diversity and structure of microbiota, as shown in Fig. (**1**). Hence, analyzing specific dietary strategies is likely the best approach to provide scientifically sound new nutritional interventions and may guide the development of national guidelines and policies on healthy eating [4, 5].



Fig. (1). The influence of food on the brain-gut microbiome system [15].

Regular aerobic exercise effectively curtails age-induced global atrophic changes within the brain. It even encourages its volumetric increase, especially in the frontal and left superior temporal lobes, which are also key regions of interest. Moderate-intensity aerobic exercise training has enhanced functional brain activity in older persons aged 60–79, improving task efficiency and better regulating behaviour and mood. Aerobic exercise has recently been shown to enhance the diversity and functional metabolism of both human and animal gut microbiomes [5]. Modifying bacterial profiles and altering the by-products generated by gut bacteria through exercise may help correct illnesses associated with obesity, metabolic disorders, inadequate nutrition, and neurological and behavioural issues. However, the influence of exercise on the gut-brain link remains undetermined [6]. This chapter aims to succinctly elucidate the intricate interplay between the microbiome, gut, and brain and clarify the effects of exercise on these interactions. Alterations to the microbiome may influence gastrointestinal functions (*e.g.*, secretion, motility, and integrity) and higher brain functions (*e.g.*, neurotransmission, neurogenesis, and behaviour), with these effects potentially.

CHAPTER 11

Gut Microbiome Modulation in Neurodegenerative Diseases: Marketed Products and Challenges

Surabhi Shakya[1], Anchal Srivastava[2], Alka Yadav[3], Anurag Verma[4] and **Amit Kumar Verma[1,*]**

[1] *Department of Pharmacy, MJP Rohilkhand University, Bareilly, India*

[2] *School of Pharmaceutical Sciences, Maharishi University of Information Technology, Lucknow, India*

[3] *Faculty, Rohilkhand College of Pharmacy, BIU, Bareilly, India*

[4] *Faculty, College of Pharmacy, Teerthankar Mahaveer University, Moradabad, India*

Abstract: The neurons in the brain and spinal cord are affected by Neurodegenerative Diseases (ND) like dementia, Parkinson's, Alzheimer's, *etc*. The change in lifestyle and habits, like smoking and alcohol consumption, causes the condition of Dysbiosis. Aging is also considered the most critical factor in the imbalance of the gut microbiota. Many researchers have suggested that the imbalance is responsible for the progression of neurodegenerative diseases in an individual. Probiotics (*Lactobacillus acidophilus*, *Bifidobacterium bifidum*, and *Lactobacillus casei*, *etc*.) have been shown in numerous *in vivo* and clinical studies to be effective candidates for preventing the progression of ND. Modifications in the gut microbiota regulate oxidative stress and the inflammatory process. Consuming healthy foods can alter the composition of beneficial microorganisms, thereby affecting the gut-brain axis. One of the nutraceutical approaches is probiotics, which not only benefits dysbiosis but also improves biological outcomes. The current chapter reviewed the clinical and preclinical data and supports the idea that modifications in the gut microbiome could improve brain neurochemistry. The modification is carried out by modifying the related pathways. The consumption of probiotics in neurodegenerative conditions highlighted the relationship between the intestinal microbiome and the nervous system.

Keywords: Probiotics, neurodegenerative, dysbiosis, lactobacillus, gut-brain axis.

INTRODUCTION

Many risk factors are associated with an individual's risk of developing a neurological disorder. Among all, the elderly population is affected the most and

* **Corresponding author Amit Kumar Verma:** Department of Pharmacy, MJP Rohilkhand University, Bareilly, India; E-mail: dramitvermamjpru@gmail.co

Ajay Kumar & Avinash Kumar (Eds.)

shows a high prevalence of the disease. Neurodegenerative implications include but are not confined to Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral disease, also known as frontotemporal memory loss, and spinocerebellar ataxias. These illnesses have a variety of causes; some impair mental and physical abilities, while others affect a person's ability to breathe, move, and talk [1]. Neurodegenerative diseases (NDs) are hereditary and sporadic conditions that result in a gradual and permanent loss of cells and the processes associated with them (axons, dendrites, and synapses), as well as a progressive decline in neuronal function. The term "degeneration," which characterizes the process by which an organ or tissue loses its form or function, and the prefix "neuro," which indicates nerve cells or brain cells, are the foundations of the word's origin [2]. Neurodegenerative diseases affect millions of residents annually. Non-communicable illnesses are primarily brought on by aging, but recent research suggests that genetic makeup and environmental variables may also raise an individual's risk for neurological disorders. In addition, even when specific genes associated with NDs are expressed, a person's local environment primarily determines the pace and extent of neurodegeneration. The most recent study said that several disorders may be the cause of just one neurodegenerative condition. Because of this, depending on the stage and type of an illness, NDs may be very dangerous and even deadly in particular circumstances [3].

The incidence of neurological diseases is linked to many viewpoints: The main risk factor for these conditions is aging; 2) Aging impacts neuroanatomical routes distinctly; 3) infectious proteins develop when these channelsdeteriorate; 4) transmissible proteins propagated along physiological pathways; 5) diseases with biological and intermittent phenotypes are comparable: and 7) neurodegenerative ailments is distinguished by heterogeneity, overlapping traits, and numerous pathology [4]. The equilibrium between adaptive and innate immunity is maintained by the gut microbiota, which controls brain function, according to a large body of studies published over the past few years. This spontaneous pathway of interaction between the gut microbiota and the brain is known as the Microbiota-Gut-Brain Axis (MGBA). Changes in the MGBA have an essential effect on the course of neurological conditions such as Alzheimer's disease through mechanisms such as greater permeation of the intestinal barrier and hyperimmune stimulation that result in chronic inflammatory conditions that can hinder the barrier between blood and brain, which encourages neural network injury, inflammation of the neurons, and subsequently neuronal degeneration [5].

Association Between Gut Microbiota and Brain

The phrase "gut microbiota" describes a broad range of microorganisms, including bacteria, viruses, and various eukaryotes such as fungi and protozoa,

that live in different ecological niches within the gastrointestinal tract. The gastrointestinal tract microbiota plays a vital role in many aspects of human physiology, including immune function, anti-infection responses, energy metabolism, and neural development. Increasing urbanization, industrialization, and advances in food or healthcare technologies—including a rise in quick-service restaurant consumption—have created a new habitat for the gut microbiota, leaving it more susceptible to damage than in the past. The relevance of gut microbiota has recently been recognized due to its crucial role in non-diagnostic infections and in controlling the differentiation, maturation, growth, and stimulation of tissue-resident immune cell types in the brain and spinal cord [6]. In addition to increasing permeability of the Blood-Brain Barrier (BBB) and the intestinal tract, gut dysbiosis—a key root cause of many digestive disorders—may also increase pro-inflammatory cytokines, monocytes, lipids, and T cells that assist in digestion *via* the microbiota-gut-brain system. Illnesses, including Parkinson's Disease (PD), Alzheimer's disease, and a condition known as amyotrophic lateral sclerosis, progress more quickly as a result. These conditions include multiple sclerosis, axonal injury, and demyelination [7]. The Irish ELDERMET study, which included 178 people aged 65+, found a correlation between global indices of health, frailty, and immunological function and the composition of the gut microbiota. According to this study, health outcomes improve with more microbial diversity. Notably, a correlation was found between gut microbiota diversity and diet; those who consumed bland, processed foods, frequently seen in nursing homes, had a less diverse microbiome, whereas those who drank a diet high in fruits and vegetables had a more diverse microbiota. Thus, one possible indicator of good aging is the multiplicity of the gut microbiota [8]. Several mechanisms exist by which the microbiota can contribute to neuroinflammation, including the production of amyloid by the microbiota or the release of endotoxic bacterial cell wall components, such as microbial lipopolysaccharides. Neuroimmune activation may be lessened by therapeutically modifying the dysbiotic gut microbiota to produce more butyrate [9].

Gut Dysbiosis is referred to as the leading cause of NDs, which follow different pathways as described below:

Production of Microbial Metabolites

The synthesis of microbial metabolites, such as Short-Chain Fatty Acids (SCFAs), is one of the most direct ways that gut microbiota affects brain function. When gut bacteria digest dietary fiber, they produce Short-Chain Fatty Acids (SCFAs) such as butyrate, acetate, and propionate. These SCFAs have anti-inflammatory properties and help to preserve the BBB’s integrity, which is crucial for shielding

SUBJECT INDEX

A

Absorption 33, 124, 127, 128, 154, 164, 253
Accumulation 37, 39, 40, 99, 100, 104, 126, 131, 194, 195, 196
Acetate 5, 31, 38, 145, 146, 211, 216, 221, 225, 248, 250
Acetylcholine 12, 100, 106, 169, 195, 212, 224
Actinobacteria 40, 42, 100, 101, 102, 104, 114, 116, 127, 129, 142, 143
Activation 5, 33, 36, 37, 42, 100, 131, 133, 134, 173, 178
Agents 48, 49, 134, 172, 179, 181, 215, 217, 218, 219, 258
Aggregation 34, 67, 71, 123, 128, 131, 134, 210
Aging 72, 103, 117, 143, 249, 267, 268, 269
Alosetron 171, 180, 182
Alpha-synuclein 37, 148, 197
Alterations 11, 103, 104, 154, 196, 277
Alzheimer 38, 39, 47, 48, 49, 144, 147, 149, 193, 194, 195, 209, 212
Anxiety levels 15, 108
Appraisals (clinically as evaluation scales/criteria) 63, 64, 65, 66, 80
Approaches 14, 28, 29, 51, 52, 54, 86, 87, 162, 170, 180, 184, 217, 233, 234, 260, 261
Astrocytes 37, 70, 105, 146, 210, 226
Attention-deficit/hyperactivity disorder (ADHD) 8, 29, 44, 45, 46
Autism spectrum disorder (ASD) 1, 2, 9, 11, 44, 45, 46
Autonomic nervous system 2, 5, 28, 62, 73, 124, 145
Axis 2, 5, 9, 10, 12, 14, 33, 37, 75, 83, 99, 123, 136, 142, 145, 152, 163, 168, 169, 174, 175, 182, 211, 224, 254, 255, 261, 268, 277

B

Bacteria 2, 5, 6, 7, 9, 11, 12, 13, 30, 31, 39, 41, 74, 104, 106, 131, 133, 142, 146, 149, 150, 152, 153, 154, 176, 184, 211, 216, 217, 219, 221, 223, 224, 228, 248, 251, 258, 275, 277
Brain-derived neurotrophic factor (BDNF) 10, 103, 107, 108, 114, 130, 192, 195, 245, 270, 271, 277, 278
Brain 13, 28, 44, 45, 53, 102, 105, 125, 146, 165, 181, 212, 245, 268, 271, 279
  function 13, 28, 44, 53, 105, 146, 181, 212, 245, 268, 271, 279
  regions 44, 45, 102, 125, 165, 279
Butyrate 31, 38, 74, 82, 86, 130, 135, 194, 212, 214, 216, 218, 221, 225, 227, 228, 230, 232, 233, 269
Butyrate-producing bacteria 127, 153, 177, 178, 198

C

Cell death 81, 150, 210
Cells 5, 11, 12, 31, 32, 36, 37, 39, 42, 68, 72, 75, 76, 84, 105, 131, 133, 145, 146, 165, 176, 192, 216, 217, 220, 224, 226, 228, 249, 251, 268, 269, 270
Central nervous system (CNS) 42, 73, 75, 78, 117, 124, 130, 131, 145, 146, 163, 164, 173, 175, 182, 211, 217, 218, 224, 245
Cerebrospinal fluid (CSF) 8, 66, 71, 85, 114, 147
Clinical 13, 15, 50, 53, 54, 64, 80, 83, 114, 115, 179, 190, 194, 195, 197, 198, 199, 209, 234, 255, 258, 273, 277, 278, 279
  practice 50, 234
  research 54, 64, 114, 197, 209
  trials 13, 15, 50, 53, 80, 83, 114, 115, 179, 190, 194, 195, 198, 199, 255, 258, 273, 277, 278, 279
Cognition 2, 8, 10, 38, 44, 109, 111, 117, 199, 212, 217, 222, 224, 226, 273, 277
Complex mechanisms 103, 147
Complexity 17, 29, 49, 50, 53, 63, 65, 87, 125
Components 4, 11, 35, 67, 69, 81, 85, 124, 132, 133, 143, 146, 153, 168, 184, 197, 199, 211, 216, 245

Concentrations 67, 103, 104, 112, 114, 116, 153, 196, 217, 219, 221, 256, 276
Cortisol 12, 15, 37, 124, 169, 174, 175, 176, 195, 256, 271, 279
Cortisol levels 37, 175, 256, 271
Criteria 63, 64, 65, 66, 80, 280
Cytokines 5, 8, 37, 75, 76, 100, 103, 104, 105, 108, 109, 112, 113, 114, 115, 116, 117, 130, 131, 133, 135, 136, 147, 148, 149, 211, 214, 218, 226, 227, 233, 269, 270, 272

D

Damage 34, 37, 66, 68, 105, 110, 130, 133, 147, 151, 197, 210, 218, 226, 227, 229, 232, 249, 269
Deficits 45, 62, 80, 103, 194, 229, 256
Degeneration 41, 62, 72, 99, 103, 126, 132, 133, 191, 209, 231, 232, 268
Delivery methods (therapeutic) 83, 150, 274
Dementia 40, 80, 99, 106, 148, 191, 195, 196, 200, 222, 229, 267, 274
Deposition 40, 149
Depression symptoms 9, 14, 252
Depressive symptoms 12, 13, 254
Diagnosis 63, 64, 65, 66, 80, 81, 82, 86, 87, 123, 148, 165
Diet 6, 8, 12, 14, 48, 52, 104, 107, 108, 109, 110, 113, 143, 194, 200, 245, 246, 247, 248, 251, 253, 254, 257, 258, 259, 260, 261, 269
Dietary 14, 40, 41, 43, 46, 48, 49, 52, 54, 246, 254, 260
  factors 246
  interventions 14, 40, 41, 43, 46, 48, 49, 52, 54, 254, 260
Digestion 30, 31, 124, 126, 127, 132, 163, 165, 166, 251, 252, 253, 257
Digestive enzymes 126, 143, 164, 165
Disorders 33, 43, 45, 46, 75, 100, 103, 104, 112, 113, 184, 197, 198, 225, 251, 252, 253, 271, 272
Disruptions 10, 11, 38, 42, 44, 69, 73, 110, 112, 128, 132, 136, 142, 144, 274
Disturbances 33, 62, 100, 127, 151, 170, 261
Diversity 6, 7, 12, 28, 30, 32, 40, 41, 48, 72, 85, 194, 213, 219, 245, 246, 247, 256, 261, 269, 280
DNA 7, 133, 210, 226, 227, 249, 259
Domain 67, 68, 150
Dopamine 37, 38, 41, 45, 102, 106, 123, 124, 128, 129, 131, 132, 164, 169, 173, 174, 210, 224, 230, 249, 270
Drugs 49, 50, 51, 61, 80, 81, 82, 83, 84, 168, 171, 172, 178, 180, 182, 184, 198, 225, 234, 274
Duration 66, 108, 116, 252, 271, 276
Dysbacteriosis 192, 193, 196, 198, 201
Dysbiosis 32, 33, 38, 40, 41, 51, 61, 62, 74, 77, 78, 87, 103, 104, 105, 107, 123, 127, 128, 131, 133, 134, 142, 143, 146, 169, 181, 191, 195, 197, 198, 232, 257, 258, 267, 269
Dysfunction 37, 53, 63, 65, 66, 72, 73, 76, 77, 123, 126, 132, 146, 147, 148, 210, 218, 270, 280
Dysregulation 27, 33, 37, 42, 45, 68, 72, 77, 126, 162, 163, 167, 173, 174, 175, 184, 212, 230

E

Early 29, 30, 43, 44, 45, 4664, 65, 77, 183
  diagnosis 64, 65, 77, 183
  life 29, 30, 43, 44, 45, 46
Ecosystem 29, 30, 73, 74, 154, 245, 249, 250
Edaravone 61, 80, 81, 84, 87, 198
Exercise 52, 110, 245, 247, 252, 253, 254, 262
Experiments 82, 102, 105, 108, 110, 111, 113, 152, 273, 278
Expression 69, 70, 76, 86, 103, 107, 113, 114, 116, 135, 150, 172, 176, 212, 218, 221, 228, 230, 232

F

Familial ALS (FALS) 63, 68, 69, 71, 72, 198
Fasting 14, 179, 245, 254
Fecal material 47, 84, 152
Fecal Microbiota Transplantation (FMT) 27, 29, 46, 47, 48, 50, 54, 61, 84, 85, 86, 134,

135, 141, 150, 151, 152, 154, 183, 193, 199, 257
Formulations 49, 215, 217, 219, 220, 226, 227, 234, 262, 272
Frontotemporal Dementia (FTD) 62, 78, 80
Fungi 6, 73, 124, 142, 216, 246, 268

G

Gamma-aminobutyric acid (GABA) 5, 8, 36, 37, 38, 75, 103, 124, 146, 173, 174, 175, 176, 177, 192, 212, 217, 221, 224, 228, 231, 270, 271, 275
Gastroparesis 125, 126, 127, 131, 132, 137
Gene expression 69, 102, 212, 218, 221, 225, 229, 230, 249, 259
Genera (microbial) 6, 74, 145, 220, 232, 262
Genes 2, 63, 67, 69, 71, 72, 78, 87, 102, 132, 145, 147, 148, 150, 212, 218, 225, 227, 230, 231, 232, 233, 260
Genetic factors 61, 62, 86, 181, 191
Genetics 9, 29, 30, 51, 67, 71, 87, 259, 260, 261
Genomics 9, 259, 260, 275
Germ-free (GF) 3, 8, 9, 10, 102, 103, 108, 109, 111, 112, 145, 146, 148, 149, 192, 197
Ghrelin 124, 127, 132, 165, 166, 179, 181, 182, 183, 211
Gut health 16, 52, 124, 125, 128, 135, 137, 183, 193, 194, 213, 220, 221, 225, 230, 250, 253, 257, 261
Gut hormones 117, 165, 166, 179, 182, 183
Gut inflammation 105, 128, 171, 177, 223, 257

H

Health outcomes 44, 213, 220, 260, 269
Hypothalamus 5, 6, 75, 145, 146, 164, 165, 174, 211

I

Imbalances 28, 32, 33, 35, 40, 41, 42, 44, 45, 46, 47, 52, 100, 124, 127, 131, 133, 216, 217, 257, 267
Immunological responses 10, 16, 117, 141, 143, 146, 270
Immunomodulation 216, 222
Improvements 12, 15, 81, 105, 107, 114, 115, 193, 194, 195, 199, 233, 254, 271, 273, 276, 277, 278
Individuals 6, 12, 14, 15, 29, 30, 42, 47, 80, 84, 86, 87, 99, 100, 114, 115, 116, 117, 222, 254, 255, 256, 259, 260, 272, 277
Intestinal 5, 32, 33, 41, 43, 75, 76, 87, 101, 113, 127, 131, 133, 146, 148, 150, 153, 164, 169, 197, 221, 245, 259, 268, 272
  barrier 5, 75, 76, 101, 113, 131, 153, 221, 245, 268, 272
  permeability 32, 33, 41, 43, 76, 87, 127, 133, 146, 148, 150, 153, 164, 169, 197, 259

L

Lactic acid 108, 109, 112, 220, 223
Learning processes 107, 111, 113, 115
Levodopa (L-DOPA) 8, 127, 128, 151, 197, 274
Lifestyle modifications 16, 49, 52, 168
Lower motor neurons (LMNs) 62, 63, 64, 65, 66, 69, 210

M

Mechanisms of action 81, 82, 84, 134, 176, 177, 215
Mediators (including inflammatory) 10, 37, 87, 117, 123, 165, 211, 254
Medications 50, 51, 52, 79, 82, 84, 127, 170, 173, 184, 197, 198, 257, 271, 272, 274, 275, 278, 279, 280
Memory 13, 100, 103, 106, 107, 108, 110, 112, 113, 114, 115, 150, 193, 194, 224, 276, 277, 279
Metabolic processes 2, 31, 124, 254
Microbial 5, 6, 7, 12, 13, 27, 28, 30, 31, 32, 34, 37, 38, 39, 40, 41, 43, 44, 49, 50, 53, 61, 76, 124, 125, 142, 163, 213, 219, 220, 245, 260, 262, 269
  communities 43, 124, 125, 142, 163, 213, 260, 262

diversity 6, 7, 12, 32, 41, 219, 245, 269
metabolites 5, 27, 28, 31, 34, 37, 38, 39, 40, 269
populations 13, 28, 30, 38, 49, 50, 76, 220
Microbiome composition 54, 136, 183, 215, 234, 273
Microbiota composition 7, 10, 35, 45, 73, 86, 102, 135, 217, 222, 230, 231
Microbiota-Gut-Brain Axis (MGBA) 5, 99, 123, 224, 255, 261, 268
Misfolding 68, 71, 87, 125, 147, 151, 210
Modulation 27, 30, 44, 45, 47, 48, 53, 106, 108, 124, 171, 173, 175, 176, 212, 213, 215, 216, 218, 219
Molecules 2, 8, 37, 39, 69, 70, 75, 111, 125, 128, 131, 133, 146, 151, 174, 211, 214, 218, 221, 228, 248, 256, 259, 260
Motor symptoms 41, 79, 80, 125, 129, 150, 193, 212, 230
Mouse models 82, 83, 104, 106, 107, 108, 109, 113, 148, 192, 193, 196, 197, 233, 234
Multiple sclerosis (MS) 27, 29, 33, 34, 37, 40, 42, 141, 144, 193, 195, 198, 199, 200, 269, 271, 274, 275
Mutations 63, 66, 67, 68, 69, 71, 72, 87, 102, 132, 148, 150, 152, 153, 197, 231

N

Nerve cells 11, 197, 246, 268
Nerves 2, 4, 35, 65, 66, 75, 77, 217, 248, 270
Neurodegenerative 34, 35, 36, 37, 38, 39, 40, 46, 47, 48, 49, 51, 52, 53, 63, 86, 105, 107, 108, 117, 131, 132, 136, 141, 142, 143, 144, 147, 209, 210, 212, 214, 215, 216, 218, 222, 224, 225, 226, 229, 234, 267, 268, 274
diseases 36, 37, 38, 40, 46, 47, 48, 49, 51, 52, 53, 63, 86, 136, 141, 212, 214, 225, 234, 267, 274
disorders (NDs) 105, 107, 108, 117, 142, 143, 144, 147, 209, 210, 214, 215, 216, 222, 224, 226, 229, 267, 268
processes 34, 35, 39, 47, 48, 53, 131, 132, 214, 218
Neurological disorders 13, 27, 28, 29, 44, 76, 79, 124, 217, 228, 258, 267, 268, 273
Neuronal 3, 37, 69, 71, 132, 133, 147, 148, 195, 196, 210, 216, 225, 231, 268, 278
death 3, 69, 132, 133, 148, 195, 196, 210, 231
function 37, 71, 147, 216, 225, 268, 278
Neurons 3, 4, 5, 12, 41, 62, 69, 70, 112, 113, 123, 125, 129, 130, 131, 132, 133, 172, 210, 226, 228, 229, 230
Neuropeptides 11, 127, 132, 178, 192
Neuroprotection 47, 61, 77, 81, 87, 130, 131, 152, 191, 193, 194, 195, 209, 212, 218, 226, 228, 229, 232, 233

P

Pain perception 11, 164, 170, 173, 174, 180
Participants 13, 15, 16, 82, 114, 199, 255, 273, 275, 276, 278, 279, 280
Pathogenesis 27, 29, 33, 34, 40, 47, 53, 63, 67, 68, 71, 73, 75, 125, 126, 128, 132, 133, 134, 142, 230, 232
Patient outcomes 27, 49, 61, 87, 184, 234
Perceived Stress Scale (PSS) 15, 279
Postbiotics 84, 86, 123, 135, 136, 137, 150, 194
Prebiotics 14, 46, 52, 85, 105, 106, 107, 108, 214, 219, 220, 221, 222, 224, 227, 234
Precursors 4, 5, 212, 215, 224, 232, 248, 249, 250
Pro-inflammatory bacteria 41, 42, 74, 136, 222, 231, 234
Pro-inflammatory cytokines 37, 39, 40, 42, 72, 75, 76, 100, 104, 105, 130, 133, 147, 214, 226, 227, 269, 270
Probiotic strains 47, 51, 176, 177, 213, 217, 218, 219, 220, 222, 228, 231, 233
Probiotic supplementation 114, 115, 116, 196, 228, 274, 279
Probiotic supplements 108, 109, 115, 199, 276, 277, 279

Probiotics 6, 16, 46, 49, 51, 107, 110, 171, 192, 213, 215, 216, 217, 219, 220, 222, 276, 277, 278, 279, 280
Production 2, 11, 33, 34, 37, 39, 42, 44, 53, 72, 75, 76, 113, 128, 129, 130, 132, 133, 134, 146, 149, 175, 176, 212, 214, 216, 218, 223, 224, 227, 228, 229, 230, 232, 249, 250, 251, 269, 270
Production of microbial metabolites 44, 53, 269
Profile 42, 51, 74, 80, 211, 234, 246, 247, 278
Proteobacteria 6, 30, 32, 34, 40, 41, 42, 74, 100, 101, 102, 127, 128, 129, 142, 143, 211
Psychobiotics 15, 123, 136, 184, 191, 246
Psychological 14, 80, 162, 163, 168, 169, 173
  factors 162, 163, 169, 173
  stress 14, 80, 162, 163, 168, 169, 173

R

Randomized clinical trial (RCT) 13, 279
Receptors 4, 5, 10, 35, 36, 103, 107, 110, 117, 145, 151, 152, 165, 171, 172, 173, 175, 178, 180, 181, 183, 192, 196, 218
Red flag symptoms 167
Reduction 32, 33, 87, 109, 110, 112, 114, 117, 126, 127, 131, 134, 135, 194, 250, 252, 271, 275
Restoration 40, 112, 145, 183, 192, 196,

S

Safety 48, 50, 51, 54, 83, 272, 274, 275, 280
Secretion 4, 11, 12, 37, 72, 102, 126, 132, 133, 164, 165, 166, 169, 171, 172, 174, 175, 247, 270
Secretory functions 62, 132
Sensitivity 10, 16, 135, 162, 163, 173, 174, 175, 177, 228, 276
Sensory
  pathways 62, 78, 169, 174
  symptoms 79
Serotonin 10, 11, 37, 38, 102, 103, 169, 170, 171, 172, 175, 176, 181, 212, 217, 224, 248, 275
  signaling 10, 172
  synthesis 176, 212
Severity 14, 38, 40, 65, 73, 77, 80, 168, 190
Short-chain fatty acids (SCFAs) 5, 8, 11, 27, 28, 31, 37, 38, 40, 41, 47, 48, 49, 74, 77, 111, 123, 124, 127, 129, 130, 131, 133, 135, 136, 145, 146, 176, 177, 178, 214, 215, 216, 220, 221, 222, 225, 226, 227, 230, 231, 233, 250, 262, 269, 270, 275
Sodium phenylbutyrate-taurursodiol 61, 80, 81, 82, 87
Species (including reactive nitrogen/bacterial) 9, 30, 34, 37, 74, 106, 111, 113, 114, 116, 132, 134, 142, 143, 210, 213, 220, 223, 232, 246, 250, 260, 272, 275
Specific pathogen-free (SPF) 9, 10, 102, 103, 107
Spasticity 62, 66, 79, 82
Synthesis 3, 5, 6, 12, 70, 153, 175, 176, 192, 211, 214, 218, 222, 224, 225, 229, 230, 231, 245, 248, 249, 269, 272
Systemic inflammation 32, 33, 38, 39, 40, 41, 42, 46, 47, 221, 222, 223, 227, 230, 231, 232, 254

T

TDP-43 proteinopathy 61, 67, 82, 87
Therapeutic 28, 30, 32, 35, 41, 46, 47, 49, 53, 54, 77, 99, 106, 134, 135, 137, 141, 153, 154, 162, 181, 190, 218, 230, 234, 252, 255
  approaches 28, 30, 41, 46, 47, 53, 77, 99, 134, 135, 137, 141, 154, 162, 181, 218, 234
  benefits 49, 153, 230, 232, 252, 255
  effects 47, 106, 190, 218, 255
  strategies 30, 32, 35, 41, 54, 77, 99, 137
Therapies 12, 16, 30, 49, 50, 51, 52, 61, 82, 134, 135, 136, 149, 162, 180, 181, 183, 184, 195, 212, 215, 219, 229, 230, 252, 255, 256, 257, 258, 259, 272
Tissues 8, 31, 33, 36, 67, 211, 225, 226, 227, 249, 268

Trimethylamine-N-oxide (TMAO) 33, 111, 147, 149
Tryptophan 5, 103, 114, 115, 176, 211, 248, 270, 276, 278

U

Upper motor neurons (UMNs) 62, 65, 66, 69

V

Vagus nerve 4, 8, 35, 36, 40, 41, 78, 105, 130, 132, 145, 164, 165, 169, 175, 176, 192, 211, 218, 270
Variability 48, 49, 50, 63, 64, 65, 87
VSL3 199, 274, 275

W

Weakened antioxidant defence 133
Weight loss 126, 148, 167

X

Xenobiotics 258, 259

Z

Zinc 249, 250, 254

Ajay Kumar

Dr. Ajay Kumar is a distinguished Pharmacologist with an M. Pharm. in Pharmacology from India's premier institute, the Indian Institute of Technology (BHU), Varanasi, and earned his Ph.D. in Pharmacology & Toxicology from the CSIR-CIMAP, Lucknow (2019). Currently working as a Professor & Head at Sardar Patel College of Pharmacy, Gorakhpur, Uttar Pradesh, India, he leads a cutting-edge research laboratory focusing on combating drug-resistant pathogens using clinical isolates. Dr. Kumar is an expert in Molecular Pharmacology, Toxicology, and Genotoxicity, with extensive experience in advanced analytical tools such as HPLC, UPLC, LC-MS/MS, Bactek, and Flow Cytometry. His lab is well-equipped for antimicrobial research, genotoxicity studies, and hepatotoxicity evaluations. Dr. Kumar is a prolific contributor to the scientific community, with over 50 research publications, 25 book chapters, 45 conference articles, and 8 granted patents. He also serves as a guest editorial board member and reviewer for several prestigious international journals.

Avinash Kumar

Dr. Avinash Kumar is an Associate Professor in the Department of Pharmaceutics at Sardar Patel College of Pharmacy, Gorakhpur, India. He earned his Bachelor of Pharmacy (B.Pharm.) degree from Rajiv Gandhi Proudyogiki Vishwavidyalaya (RGPV), Bhopal. He completed his Master of Science in Pharmacy (Biotechnology) from the National Institute of Pharmaceutical Education and Research, Hajipur (NIPER Hajipur), one of India's premier institutions for pharmaceutical education and research. Dr. Kumar pursued his doctoral research through a joint Ph.D. program under the Academy of Scientific and Innovative Research and RMIT University, gaining international research exposure and interdisciplinary expertise. His research interests encompass pharmaceutics, pharmaceutical biotechnology, nanotechnology-based drug delivery systems, biomaterials, and advanced therapeutic formulations. With a strong commitment to academic excellence and scientific innovation, Dr. Kumar has contributed to research publications, student mentoring, and the advancement of pharmaceutical education. He is passionate about translating cutting-edge scientific discoveries into practical healthcare solutions and fostering a research-oriented learning environment for future pharmacists and scientists. Through his academic and research endeavors, Dr. Kumar continues to promote innovation, critical thinking, and excellence in pharmaceutical sciences, making meaningful contributions to both academia and the broader healthcare community.